



BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Measurement of psychosocial consequences in a randomised cancer screening trial: how attrition bias affects these estimates

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-030871
Article Type:	Research
Date Submitted by the Author:	11-Apr-2019
Complete List of Authors:	Malmqvist, Jessica; University of Copenhagen, Department of Public Health Siersma, Volkert; University of Copenhagen, Department of Public Health Thorsen, Hanne; University of Copenhagen, Department of Public Health Heleno, B; Universidade Nova de Lisboa, Rasmussen, Jakob; University of Copenhagen, The Research Unit for General Practice Brodersen, John; University of Copenhagen, Centre of Research & Education in General Practice Primary Health Care Research Unit, Zealand Region
Keywords:	Bias, Mass screening, Patient dropout, Lung neoplasms

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Measurement of psychosocial consequences in a randomised cancer screening trial: how attrition bias affects these estimates

Jessica Malmqvist^{ac}, Volkert Siersma^a, Hanne Thorsen^a, Bruno Heleno^b Jakob Fraes Rasmussen^a, John Brodersen^{ac}

^a The Section of General Practice and Research Unit for General Practice, University of Copenhagen, Øster Farimagsgade 5, 24Q, 1014 Copenhagen, Denmark.

^b CEDOC, Chronic Diseases Research Centre, NOVA Medical School/Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, Campo dos Mártires da Pátria, 130, 1169-056 Lisbon, Portugal

^c The Primary Health Care Research Unit, Region Zealand, Denmark

Corresponding author:

Jessica Malmqvist

jessica.malmqvist@sund.ku.dk

Phone number: +45-35332583

Fax number: +45-35327946

Keywords

bias, mass screening, lung neoplasms, patient dropouts

Word count

2780

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

21

22 **Abstract**

23 **Objectives:** We investigated if psychosocial status, socio-demographics and smoking status
24 affected non-response in the control group in the randomized Danish Lung Cancer Screening Trial
25 (DLCST).

26 **Design & setting:** This study was an observational study nested in the DLCST. Due to a large
27 dropout in the control group in the second screening round we made an additional effort to
28 collect questionnaire data from dropouts in this group in the third screening round. We used a
29 condition-specific questionnaire to assess psychosocial status. We analysed the differences in
30 psychosocial status in the third and preceding rounds between dropouts and attenders in the
31 control group in multivariable linear regression models adjusted for socio-demographics and
32 smoking status reported at baseline. Differences in socio-demographics and smoking status were
33 analysed with chi-squared tests.

34 **Primary outcome measure:** Primary outcome was psychosocial status.

35 **Participants:** All control persons still participating at the third screening round in the DLCST were
36 included.

37 **Results:** Dropouts in the third round had significantly worse psychosocial status than attenders in
38 the scales: “Behaviour” 0.77 (99% CI 0.18;1.36), “Self-blame” 0.59 (99% CI 0.14;1.04), “Focus on
39 airway symptoms” 0.22 (99% CI 0.08;0.36), “Stigmatisation” 0.51 (99% CI 0.16;0.86), “Introvert”
40 0.56 (99% CI 0.23;0.89), and “Harms of smoking” 0.35 (99% CI 0.11;0.59). Moreover, Dropouts had
41 worse scores than attenders in the preceding screening rounds. Dropouts also reported worse
42 socio-demographics at baseline.

Conclusions: Dropouts had a significantly worse psychosocial status and worse socio-demographics compared with attenders. The results of our study contribute with evidence of non-response and attrition driven by psychosocial status, which in turn may be influenced by the screening intervention itself. This can be used to adjust cancer screening trial results for bias due to differential dropout.

Trial registration: The trial is registered in [Clinicaltrials.gov](https://clinicaltrials.gov) Protocol Registration System (identification no. [NCT00496977](https://clinicaltrials.gov/ct2/show/study/NCT00496977))

Article summary

Strengths and limitations

- Use of a condition-specific questionnaire with adequate psychometric properties ensured valid measures.
- Patient-reported data on dropouts gave valuable empirical insight in drivers for dropout.
- Testing a previously hypothesized model for dropout empirically is another strength of the study.
- No comparison between dropouts in the intervention and the control group was performed.
- No longer-term follow up on dropouts was performed.

Introduction

Attrition and non-response may affect trial results and introduce bias in randomized controlled trials (RCTs).[1,2] Non-response reduces the power of the trial and, if non-response differs

1
2
3
4 65 between the randomized groups, conventional effect estimates can be biased.[2] While we cannot
5
6
7 66 change the loss of power, we may remove bias due to differential non-response if we know and
8
9 67 have measured the factors that cause this non-response.[3] For some outcome measures, such as
10
11 68 disease incidence or mortality, attrition can be partially addressed if data can be obtained from
12
13
14 69 national electronic registers. Non-response will be larger for outcome measures that depend on
15
16 70 direct data collection such as clinical measurements and patient reported outcome measures
17
18
19 71 (PROMs). Moreover, the factors driving non-response for these measures may be very
20
21 72 heterogeneous and may also be driven by the experiences of the trial participants in the trial
22
23
24 73 process.
25
26 74 The problems with differential attrition may be aggravated in trials assessing psychosocial
27
28 75 consequences of cancer screening as well as other interventions where it is impossible to blind
29
30 76 participants to allocation. Notably, a control group not offered screening may be less inclined to
31
32 77 return questionnaires enquiring into their experiences with a potentially beneficial intervention
33
34 78 they did not receive. Despite these potential problems, few cancer screening RCTs have reported
35
36 79 on non-response let alone adjusted for potential differential attrition.[4–7] The trials that do,
37
38 80 seldom report on the factors involved in non-response. Since cancer screening trials are
39
40
41 81 investigating potentially life-threatening diseases there may be emotional drivers of non-response,
42
43 82 not typical for trials in general. Hence, it is of interest to know which factors drive non-response in
44
45 83 PROMs in cancer screening trials as this data is to be collected in these trials and then used in
46
47 84 adjusting for differential non-response.
48
49
50
51
52
53 85
54
55 86 The Danish Lung Cancer Screening Trial (DLCST) was an RCT including five annual screening rounds
56
57
58 87 of low-dose chest computed tomography (CT) plus clinical examinations in the intervention group
59
60

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES).

compared with annual clinical examinations only in the control group.[8] Furthermore, all the participants were asked to complete a condition-specific questionnaire, measuring psychosocial consequences of lung cancer screening at these annual clinical assessments.[9] The results showed that people experienced negative psychosocial consequences merely by participating in the trial, and that negative consequences were higher for participants allocated to the control group.[7,10] A large number of controls did not attend the second annual examination (n=513, 26.1%) while dropout in the intervention group was low (n=71, 3.5%) (*Fig. 1*). To adjust for this differential dropout, inverse probability weighting was used.[7] In this method the observed outcomes are weighted with the inverse of the probability of being non missing.[3] We hypothesised that these probabilities were adequately estimated from socio-demographic profile including smoking status, randomization group and psychosocial status in previous rounds.[7,11–13]

If these hypotheses were confirmed, then these factors would explain the witnessed difference in response between the trial groups and could be used to render them comparable. Analysed without such adjustments the assessment of the trial groups, and thereby the means of the scores from the responses to the questionnaire from the remaining trial participants would no longer be comparable.[14] Hence, the assessment of psychosocial harms of lung cancer screening could be biased.

Therefore, the overall aim of this study was to empirically assess whether control participants who dropped out of the study had different psychosocial profiles compared with control participants who attended the study.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Materials and methods

Study design and population

The design and study population of DLCST have been described in detail previously.[7,8] Briefly, the DLCST was an RCT, conducted at the Copenhagen University hospital Gentofte in Denmark from October 2004 to March 2010. Heavy current and former smokers (at least 20 pack-years), aged 50-70 years old, were randomized to either five rounds of screening with low-dose CT-scans including clinical examinations (n=2052) or five clinical examinations only (n=2052). In the enrolment visit, participants provided socio-demographic data, lifestyle and health information (including smoking status), completed a questionnaire on their psychosocial status and underwent spirometry. Participants randomized to screening also had a low-dose chest CT-scan within one month of randomisation. In the following screening rounds, participants in the screened and control groups were invited to a visit in the screening clinic where lung function tests were performed, and questionnaires concerning health, lifestyle, smoking habits and psychosocial status were completed and lung function tests were performed. Participants randomized to screening also received a low-dose chest CT-scan.

This study is an observational study nested in the DLCST. During the second screening round, the steering committee noted that a large number of control participants did not attend the screening clinic visit when compared with the number of screened participants. Thus, the committee decided to make additional efforts to collect questionnaire data for dropouts in the control group in the third screening round to perform post hoc analyses on whether psychosocial status was an influencing factor (*Fig.2*).

During the third round, participants in the control group who dropped out were contacted by phone and part 1 of the questionnaire was sent with a postage paid envelope to those who gave

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES)

their oral consent. The data was used to supplement the data collected on site at the screening clinic.[7] This yielded three groups within the control group, denoting the extent of response to the clinical examination and the questionnaire defined as:

1. *Attenders*: participants who attended the third screening round.
2. *Dropouts*:
 - a) *Responders*: participants who dropped out but completed and returned the COS-LC after the phone interview.
 - b) *Non-responders*: participants who dropped out and did not complete the COS-LC.

Outcomes & Questionnaires

Primary outcome was psychosocial status measured with the Consequences Of Screening for Lung Cancer (COS-LC) questionnaire.[9] Part 1 of COS-LC comprised nine scales measuring various aspects of consequences of screening; a second part of COS-LC addressed the screening outcome and was therefore not applicable to the present analysis. Moreover, the primary part of COS-LC included four core scales: "Anxiety", "Behaviour", "Dejection" and "Sleep" that are not lung cancer specific. These scales have originally been developed from a breast cancer screening assessment instrument.[15] Additionally COS-LC comprised five lung cancer specific scales: "Self-blame", "Focus on airway symptoms", "Stigmatisation", "Introvert", and "Harm of smoking", which were developed from focus groups and other screening assessment instruments during the first DLCST screening round.[9,15] Therefore, only the core scales were used in the first round, while in the following four screening rounds both the core scales and the lung cancer specific scales were used to assess psychosocial status.[9]

1
2
3
4 157
5
6
7 158 **Statistics**
8
9 159 *Covariates*
10
11
12 160 Socio-demographic characteristics were defined by: social class (I highest social class to V lowest
13
14 161 social class), school and vocational education (from 9 years of elementary school to a university
15
16 162 education), employment status, living alone, smoking status (current or former smoker), smoking
17
18
19 163 history (pack-years), motivation for smoking cessation (from very strong to no wish to quit) and
20
21 164 Charlson Comorbidity Index (CCI). Furthermore, we adjusted for region of residence (Denmark is
22
23
24 165 divided into five health-administrative regions).
25
26 166
27
28
29 167 *Statistical analyses*
30
31 168 We performed three different analyses:
32
33
34 169 1. Analyses of differences in psychosocial status in the **third** round between *Attend*ers and
35
36 170 *Dropout-responders*.
37
38
39 171 2. Analyses of differences in psychosocial status in the **second** round between *Attend*ers,
40
41 172 *Dropout-responders* and *Dropout-non-responders*.
42
43 173 3. Analyses of differences in psychosocial status in the **first** round, between *Attend*ers,
44
45
46 174 *Dropout-responders* and *Dropout-non-responders*.
47
48 175 Covariates at the first screening round were compared between *Attend*ers and *Dropouts* by chi-
49
50
51 176 squared tests (categorical characteristics) and t-tests (continuous characteristics). Analyses of
52
53 177 psychosocial status at various points in the follow-up were performed in linear regression models
54
55
56 178 both unadjusted and in multivariable models adjusted for sex, age, region of residence, social
57
58 179 class, living alone, smoking status, pack years, motivation for smoking cessation and CCI. To adjust
59
60

for multiple testing a p-value <0.01 was considered statistically significant. All analyses were performed with SAS 9.4 (SAS Institute, Inc., Cary, NC).

Patient and Public Involvement

Patients and public were not involved in the design of the study.

Results

The inclusion process and participation rate of the DLCST are illustrated in Figure 1. The participation rate in the control group fell from 73.9% in the second round to 57.5% in the fourth round. The participation rate increased in the fifth, final, round (68.9%).

Figure 2 depicts the inclusion process of the present study and showed a dropout rate of 29.6% (n=607) in the third screening round with a higher distribution of *Dropout-non-responders* (16.9% n=347) compared with *Dropout-responders* (12.7% n=260).

In the first screening round we compared differences in socio-demographic characteristics in the two overarching groups (*Attendees*, *Droptouts*) (Table 1).

Table 1, Socio-demographics

	Missing observations, total	Attendees n=1388 n (%)**	Dropouts n=607 n(%)**	p-value
Covariates	n	n (%)**	n(%)**	
Sex	0			0.0963
Male		773 (55.7)	313 (51.6)	
Female		615 (44.3)	294 (48.4)	
Age, mean (SD)	0	57.4 (4.7)	56.9 (4.9)	0.0538
Social class	12			0.0079
I (highest social status)		103 (7.5)	35 (5.8)	
II		296 (21.4)	100 (16.6)	
III		256 (18.5)	114 (18.9)	
IV		375 (27.2)	161 (26.7)	
V (lowest social status)		168 (12.2)	107 (17.7)	
Employed, social class uncertain		112 (8.1)	49 (8.1)	
Outside the labour market		70 (5.1)	37 (6.1)	
School education	5			0.7765
9 years of elementary school		473 (34.2)	220 (36.3)	
10 years of elementary school		541 (39.1)	231 (38.1)	
3 years of upper secondary school		363 (26.2)	153 (25.3)	
Other		7 (0.5)	2 (0.3)	
Vocational education	4			0.1267
None		124 (9.0)	72 (11.9)	
Semi-skilled worker		17 (1.2)	10 (1.7)	
Vocational training		491 (35.4)	212 (35.0)	
Short further education		142 (10.2)	48 (7.9)	
Middle range training		357 (25.8)	167 (27.6)	
Long further education		153 (11.0)	64 (10.6)	
Other		102 (7.4)	32 (5.3)	
Employment status	6			0.8394
Employed		901 (65.2)	387 (63.9)	
Studying		8 (0.6)	4 (0.7)	
Job seeking		67 (4.8)	35 (5.8)	
Retired		407 (29.4)	180 (29.7)	
CCI, mean (SD)		0.26 (0.73)	0.31 (0.83)	0.0062
Living alone	17			0.0057
No		1011 (73.5)	405 (67.3)	
Yes		365 (26.5)	197 (32.7)	
Smoking status	0			0.0122
Current smoker		1046 (75.4)	489 (80.6)	
Former smoker		342 (24.6)	118 (19.4)	

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Enseignement Supérieur (ABES).

Pack-years, <i>mean (SD)</i>	4	35.7 (13.7)	35.8 (12.3)	0.4207
Motivation for smoking cessation	30			0.0540
Very strong		141 (10.3)	74 (12.4)	
Strong		324 (23.7)	166 (27.8)	
Weak		331 (24.2)	144 (24.8)	
Very weak		116 (8.5)	42 (7.0)	
No wish to quit		113 (8.3)	54 (9.0)	
Current non-smoker		342 (25.0)	118 (19.7)	

For peer review only

**Except when indicated in the leftmost column that the mean and standard deviation (SD) are listed

There was a significant difference between the study groups for social class with more *Dropouts* in the lowest social class (V) and a greater number of *Attendees* in the highest social classes (I-II). Moreover, *Dropouts* had a significantly higher CCI score indicating that they had more severe or a greater number of co-occurring conditions than *Attendees*. They were also to a greater extent living alone. Furthermore, a non-statistically significant trend of more current smokers with a higher wish of smoking cessation were seen among *Dropouts*. The results of the third screening round are listed in Table 2.

Table 2, Differences in psychosocial status in the third screening round

	Range of values	Responding rate per item n/n	Attendees n=1388 mean (SD)	Dropout- responders n=260 mean (SD)	p-value	Difference in scores between the two groups mean (99%CI) ^a	p-value adjusted
COS-scales							
Anxiety	0-18	1349/249	1.7 (2.8)	2.1 (3.2)	0.0441	0.38 (-0.13;0.89)	0.0548
Behaviour	0-21	1343/246	2.1 (3.1)	2.9 (3.8)	<0.001	0.77 (0.18;1.36)	<0.001
Dejection	0-18	1354/255	1.9 (3.0)	2.4 (3.5)	0.013	0.49 (-0.06;1.04)	0.0225
Sleep	0-12	1357/252	1.9 (2.6)	2.3 (3.0)	0.041	0.35 (-0.12;0.82)	0.0599
COS-LC scales							
Self-blame	0-15	1356/234	2.2 (2.8)	3.1 (3.8)	<0.001	0.59 (0.14;1.04)	<0.001
Focus on airway symptoms	0-24	1363/239	0.3 (0.8)	0.6 (1.0)	<0.001	0.22 (0.08;0.36)	<0.001
Stigmatisation	0-12	1361/241	1.5 (1.9)	2.1 (2.4)	<0.001	0.51 (0.16;0.86)	<0.001
Introvert	0-18	1361/243	1.3 (1.8)	1.8 (2.2)	<0.001	0.56 (0.23;0.89)	<0.001
Harms of smoking	0-6	1356/248	0.9 (1.2)	1.3 (1.6)	<0.001	0.35 (0.11;0.59)	<0.001

^a) A positive value of the difference indicates that the persons that were interviewed by phone and later returned COS-LC had on average higher scores, i.e. more negative outcomes (e.g. higher anxiety) than the persons that showed up and completed the COS-LC on site. The differences are adjusted for sex, age, region of residence, social group, living alone, smoking status, pack years, motivation for smoking cessation and CCI. The continuous values variables (age and pack years) are included as a quadratic function as to allow for possible nonlinear effects.

In the core questionnaire COS (Consequences of Screening), *Dropout-responders* had a statistically significant higher (worse) score than *Attendees* in the scale “Behaviour”. This effect was still present when adjusting for covariates. Moreover, there was a non-significant trend of worse scores in all COS scales among *Dropout-responders*. In the lung cancer specific part of the COS-LC,

Dropout-responders had statistically significantly higher scores in all scales both crude and adjusted.

Table 3 shows differences in psychosocial status between all three subgroups in the second screening round.

Table 3, Differences in psychosocial status in the second screening round

	Range of values	Responding rate per item n/n/n	Attendees n=1388	Dropout- responders n=260	Dropout-non- responders n=347	p-value	p-value adjusted ^a
COS scales, mean (SD)							
Anxiety	0-18	1201/117/89	1.6 (2.7)	2.0 (3.0)	2.6 (3.8)	0.003	0.018
Behaviour	0-21	1195/114/88	1.9 (2.9)	2.4 (3.3)	2.8 (4.0)	0.012	0.071
Dejection	0-18	1217/117/87	1.8 (2.8)	2.3 (3.3)	3.0 (4.0)	<0.001	<0.001
Sleep	0-12	1220/116/88	1.7 (2.5)	2.3 (2.9)	2.6 (3.2)	<0.001	0.002
COS-LC scales, mean (SD)							
Self-blame	0-15	1210/118/88	1.7 (2.3)	2.1 (2.4)	2.6 (3.0)	<0.001	0.005
Focus on airway symptoms	0-24	1226/118/90	0.4 (0.8)	0.4 (0.8)	0.5 (0.9)	0.408	0.579
Stigmatisation	0-12	1225/121/90	1.5 (1.9)	1.8 (2.1)	2.1 (2.4)	0.028	0.146
Introvert	0-18	1223/116/90	1.3 (1.8)	1.8 (2.0)	1.4 (1.8)	0.012	0.021
Harms of smoking	0-6	1232/118/89	1.1 (1.3)	1.3 (1.3)	1.2 (1.4)	0.134	0.422

^a A test for differences between the three groups adjusted for sex, age, region of residence, social group, living alone, smoking status, pack years, motivation for smoking cessation and the CCI. The continuous values variables (age and pack years) are included as a quadratic function as to allow for possible nonlinear effects.

Dropouts had significantly worse crude scores compared with *Attendees* in all but one scale

("Behaviour") in the COS scales. When adjusting for covariates the difference in scores was still significant in two scales "Dejection" and "Sleep". In the lung cancer specific part, the crude and adjusted "Self-blame"-scale score was significantly worse for *Dropouts*.

The differences in psychosocial status in the first screening round between *Attendees*, *Dropout-responders* and *Dropout-non-responders* showed a statistically significant worse unadjusted score in all but one COS-scale ("Behaviour"), for the two *Dropout* subgroups (Table 4). That effect disappeared in all but one scale, "Anxiety" when adjusting for covariates.

Table 4, Differences in psychosocial status in the first screening round

	Range of values	Responding rate per item n/n/n	Attendees n=1388 mean (SD)	Dropout-responders n=260 mean (SD)	Dropout-non-responders n=347 mean (SD)	p-value	p-value adjusted ^a
COS-scales							
Anxiety	0-18	1353/253/334	1.46 (2.16)	1.75 (2.54)	2.11 (2.66)	<0.001	0.0028
Behaviour	0-21	1365/257/340	0.75 (1.89)	1.05 (2.44)	1.04 (2.43)	0.0134	0.0976
Dejection	0-18	1372/257/339	1.25 (2.05)	1.54 (2.48)	1.68 (2.33)	0.0018	0.0512
Sleep	0-12	1368/253/344	0.62 (1.64)	0.86 (1.98)	0.90 (1.86)	0.0072	0.0530

^a) The differences are adjusted for sex, age, region of residence, social group, living alone, smoking status, pack years, motivation for smoking cessation and CCI. The continuous values variables (age and pack years) are included as a quadratic function as to allow for possible nonlinear effects.

Discussion

The present study showed considerable attrition in the control group of the DLCST. Data in the control group was not missing at random. Individuals who dropped out had less favourable baseline socio-demographic profile when compared with attendees. More importantly, individuals who dropped out from their annual clinical work-up had worse psychosocial status than the individuals who attended the clinic in the previous rounds. This can be used to adjust for differential dropout. Furthermore, these individuals also had worse psychosocial status during their missed round (assessed in the present study in the third round). This cannot be used to adjust differential dropout because this information is generally not available but proves the concept.

The use of a condition-specific questionnaire is a strength of the study. Previous research has demonstrated that condition-specific questionnaires are superior to generic questionnaires when measuring psychosocial consequences in cancer screening settings.[16] Furthermore, we used an appropriate longitudinal design i.e. we collected data at the same timepoints for both *Attendees*

and *Dropouts* at various times in the trial, as well as we measured psychosocial status in both groups at baseline.[17] A limitation of the study is that we did not collect psychosocial outcomes of dropouts in the intervention group. This study was designed to gain knowledge of factors motivating such a large drop in participation in the control group. In hindsight, data on dropouts in the screened group could further help us understand the reasons for differential dropout. In addition to the DLCST, two other trials assessed psychosocial consequences in lung cancer screening with low-dose CT.[6,18] Participants in the NELSON trial were invited to complete questionnaires at baseline and at the second round of screening (two years after baseline screening). Participants in the UKLS completed a questionnaire at baseline, two weeks after randomisation/CT-scan and 10-29 months after baseline. Unlike the DLCST, in these two trials the control group were not invited to an annual visit at the screening clinic. Although there were some differences in study design, dropout rates in the control groups in these three trials were similar and in all three trials there was a differential dropout rate between the intervention and control group. Differences between attenders and participants who dropped out were reported in the UKLS trial. As in the DLCST, dropouts had worse socio-demographic profile i.e. lower social class, and they were more likely single, younger and current smokers compared with attenders. However, these were pooled estimates for both the screening group and the control group. In individuals diagnosed with cancer, anxiety and worse health-related quality of life have been associated with dropout, which is consistent with our findings.[19] Since *Dropouts* in our study experienced a higher level of anxiety than *Attenders* in the first screening round (i.e. baseline), this could have been the motivation for attending the trial; to get reassured of being healthy.[20] Therefore, randomization to the control group may have caused disappointment, but also attention drawn to not being part of a possibly beneficial intervention.[21] For example, the

1
2
3
4 332 secretary in the screening clinic received calls from participants randomized to the control group
5
6
7 333 expressing their disappointment of not being screened. Furthermore, the trial put focus on the
8
9 334 harms of smoking, which could have increased the anxiety and fear of disease in this subgroup
10
11
12 335 even more, which may have been a reason to subsequent dropout.
13
14 336 Low social status, younger age and current smoking status have previously been seen among
15
16 337 dropouts in lung health studies.[22–25] A systematic review reporting dropout from longitudinal
17
18
19 338 studies in elderly concluded that higher age and declining health were high predictors of dropout.
20
21 339 The latter is in agreement with our findings, although higher age is in contrast to our findings.[26]
22
23
24 340 To our knowledge, this is the first cancer screening study testing hypotheses on reasons for
25
26 341 differential dropout empirically. The results of this study confirmed the hypotheses we made in
27
28
29 342 our previous study, using inverse probability weighting to adjust for differential dropout.[3,7,27]
30
31 343 More importantly, the results of the two other lung cancer screening trials investigating dropout
32
33
34 344 are consistent with ours. Hence, it is plausible that our results are generalisable to other cancer
35
36 345 screening trials as well.
37
38 346 Therefore, future cancer screening trials should concurrently assess psychosocial status during the
39
40
41 347 trial, not only to be able to assess the psychosocial effect of screening, but also to use this
42
43 348 information to adjust any effect in the trial for bias due to differential attrition.
44
45
46 349

47
48 350 **Conclusions**
49

50
51 351 In conclusion, *Dropouts* in the control group in the DLCST had a worse psychosocial status and a
52
53 352 less favourable socio-demographic profile than *Attendees*.
54
55
56
57
58
59
60

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES)

The results of our study contribute with evidence of non-response driven by psychosocial status, which in turn may be influenced by the screening intervention itself. This can be used to adjust cancer screening trial results for bias due to differential dropout.

Abbreviations

RCT: Randomized controlled trial; PROM: Patient-reported outcome measure; CT: Computed tomography; DLCST: Danish Lung Cancer Screening Trial; COS-LC: Consequences of screening in lung cancer; COS: Consequences of screening; CCI: Charlson comorbidity index

Declarations

Ethics approval and consent to participate

The Ethical Committee of Copenhagen County approved the DLCST on 31 January 2003.

All participants signed an informed consent form. The trial is registered in [Clinical.Trials.gov](https://clinicaltrials.gov) Protocol Registration System (identification no. [NCT00496977](https://clinicaltrials.gov/ct2/show/study?term=NCT00496977))

Availability of data and materials

The corresponding author can provide the questionnaires and datasets generated and analysed during the study on reasonable request.

Competing interests

None declared.

Funding

1
2
3
4 376 This work was supported by the Danish Ministry of Interior and Health, grant number 0900814.
5
6
7 377 The funding source had no role in study design, data collection and analysis, decision to publish, or
8
9 378 preparation of the manuscript.
10
11
12 379

13
14 380 **Author contributions**

15
16 381 JB and HT developed and designed the study. JB, HT and the DLCST staff collected data. VS
17
18
19 382 performed the statistical analyses. JM drafted the manuscript. JB, HT, BH, JFR, and VS all
20
21 383 contributed to parts of the manuscript as well as revisions of the manuscript. All authors approved
22
23
24 384 the final version of the manuscript, and no editorial assistance was received. All authors had full
25
26 385 access to all data in the study and are responsible of data retention and the accuracy of the data
27
28
29 386 analysis. JM and JB are guarantors of the study.
30

31 387
32
33 388 **Acknowledgement**

34
35
36 389 We wish to thank data manager Willy Karlslund for his contribution to generation of the databases
37
38
39 390 and we also wish to thank the DLCST steering committee.
40

41 391
42
43
44 392 **Fig.1 Flowchart, DLCST**

45
46
47
48 393 **Fig.2 Flowchart, present study**
49
50
51
52
53
54
55
56
57
58
59
60

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES).

References

1. Tierney JF. Investigating patient exclusion bias in meta-analysis. *Int J Epidemiol* [Internet]. 2004;34:79–87. Available from: <https://academic.oup.com/ije/article-lookup/doi/10.1093/ije/dyh300>
2. Zhang Y, Alyass A, Vanniyasingam T, Sadeghirad B, Flórez ID, Pichika SC, et al. A systematic survey of the methods literature on the reporting quality and optimal methods of handling participants with missing outcome data for continuous outcomes in randomized controlled trials. *J Clin Epidemiol* [Internet]. 2017;88:67–80. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/28579378>
3. Dufouil C, Brayne C, Clayton D. Analysis of longitudinal studies with death and drop-out: a case study. *Stat Med* [Internet]. 2004;23:2215–26. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/15236426>
4. Humphrey LL, Deffebach M, Pappas M, Baumann C, Artis K, Mitchell JP, et al. Screening for lung cancer with low-dose computed tomography: a systematic review to update the US Preventive services task force recommendation. *Ann Intern Med* [Internet]. 2013 [cited 2014 Feb 26];159:411–20. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/23897166>
5. Wu GX, Raz DJ, Brown L, Sun V. Psychological Burden Associated With Lung Cancer Screening: A Systematic Review. *Clin Lung Cancer* [Internet]. 2016;17:315–24. Available from: <http://linkinghub.elsevier.com/retrieve/pii/S1525730416300535>
6. Brain K, Lifford KJ, Carter B, Burke O, McDonald F, Devaraj A, et al. Long-term psychosocial outcomes of low-dose CT screening: results of the UK Lung Cancer Screening randomised controlled trial. *Thorax* [Internet]. 2016;71:996–1005. Available from:

1
2
3
4 417 <http://thorax.bmj.com/lookup/doi/10.1136/thoraxjnl-2016-208283>
5
6
7 418 7. Rasmussen JF, Siersma V, Pedersen JH, Brodersen J. Psychosocial consequences in the Danish
8
9
10 419 randomised controlled lung cancer screening trial (DLCST). Lung Cancer [Internet]. 2015;87:65–72.
11
12 420 Available from: <http://www.ncbi.nlm.nih.gov/pubmed/25433982>
13
14
15 421 8. Pedersen JH, Ashraf H, Dirksen A, Bach K, Hansen H, Toennesen P, et al. The Danish randomized
16
17 422 lung cancer CT screening trial--overall design and results of the prevalence round. J Thorac Oncol
18
19
20 423 [Internet]. 2009 [cited 2013 Sep 18];4:608–14. Available from:
21
22 424 <http://www.ncbi.nlm.nih.gov/pubmed/19357536>
23
24
25 425 9. Brodersen J, Thorsen H, Kreiner S. Consequences of screening in lung cancer: development and
26
27 426 dimensionality of a questionnaire. Value Health [Internet]. 2010 [cited 2013 Oct 1];13:601–12.
28
29
30 427 Available from: <http://www.ncbi.nlm.nih.gov/pubmed/20345552>
31
32
33 428 10. Aggestrup LM, Hestbech MS, Siersma V, Pedersen JH, Brodersen J. Psychosocial consequences
34
35 429 of allocation to lung cancer screening: a randomised controlled trial. BMJ Open [Internet]. 2012
36
37
38 430 [cited 2013 Oct 1];2:e000663. Available from:
39
40 431 <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3293139&tool=pmcentrez&renderty>
41
42 432 [pe=abstract](http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3293139&tool=pmcentrez&renderty)
43
44
45 433 11. Heydarpour B, Saeidi M, Ezzati P, Soroush A, Komasi S. Sociodemographic Predictors in Failure
46
47 434 to Complete Outpatient Cardiac Rehabilitation. Ann Rehabil Med [Internet]. 2015;39:863–71.
48
49
50 435 Available from: <http://www.ncbi.nlm.nih.gov/pubmed/26798599>
51
52
53 436 12. de Graaf R, van Dorsselaer S, Tuithof M, ten Have M. Sociodemographic and psychiatric
54
55 437 predictors of attrition in a prospective psychiatric epidemiological study among the general
56
57
58 438 population. Result of the Netherlands Mental Health Survey and Incidence Study-2. Compr
59
60

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Enregistrement Supérieur (ABES).

- Psychiatry [Internet]. 2013;54:1131–9. Available from:
<http://linkinghub.elsevier.com/retrieve/pii/S0010440X13001284>
13. Field JK, Duffy SW, Baldwin DR, Whynes DK, Devaraj A, Brain KE, et al. UK Lung Cancer RCT Pilot Screening Trial: baseline findings from the screening arm provide evidence for the potential implementation of lung cancer screening. *Thorax* [Internet]. 2015;1–10. Available from:
<http://www.ncbi.nlm.nih.gov/pubmed/26645413>
14. McCaffery KJ. Assessing psychosocial/quality of life outcomes in screening: how do we do it better? *J Epidemiol Community Heal* [Internet]. 2004;58:968–70. Available from:
<http://jech.bmj.com/cgi/doi/10.1136/jech.2004.025114>
15. Brodersen J, Thorsen H. Consequences of Screening in Breast Cancer (COS-BC): development of a questionnaire. *Scand J Prim Health Care* [Internet]. 2008 [cited 2013 Oct 1];26:251–6. Available from:
<http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3406644&tool=pmcentrez&rendertype=abstract>
16. Brodersen J, Thorsen H, Cockburn J. The adequacy of measurement of short and long-term consequences of false-positive screening mammography. *J Med Screen*. 2004;11:39–44.
17. DeFrank JT, Barclay C, Sheridan S, Brewer NT, Gilliam M, Moon AM, et al. The psychological harms of screening: the evidence we have versus the evidence we need. *J Gen Intern Med* [Internet]. 2015;30:242–8. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/25150033>
18. van den Bergh KAM, Essink-Bot ML, Borsboom GJJM, Scholten ET, van Klaveren RJ, de Koning HJ. Long-term effects of lung cancer computed tomography screening on health-related quality of life: the NELSON trial. *Eur Respir J* [Internet]. 2011 [cited 2014 Oct 3];38:154–61. Available from:

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

<http://www.ncbi.nlm.nih.gov/pubmed/21148229>

19. Mercieca-Bebber RL, Price MA, Bell ML, King MT, Webb PM, Butow PN, et al. Ovarian cancer study dropouts had worse health-related quality of life and psychosocial symptoms at baseline and over time. *Asia Pac J Clin Oncol* [Internet]. 2017;13:e381–8. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/27573704>

20. Østerø J, Siersma V, Brodersen J. Breast cancer screening implementation and reassurance. *Eur J Public Health*. 2014;24:258–63.

21. Wendler D, Krohmal B, Emanuel EJ, Grady C. Why patients continue to participate in clinical research. *Arch Intern Med* [Internet]. 2008 [cited 2013 Oct 1];168:1294–9. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/18574086>

22. Snow WM, Connett JE, Sharma S, Murray RP. Predictors of attendance and dropout at the Lung Health Study 11-year follow-up. *Contemp Clin Trials* [Internet]. 2007;28:25–32. Available from: <http://linkinghub.elsevier.com/retrieve/pii/S1551714406001157>


23. Nohlert E, Öhrvik J, Helgason ÁR. Non-responders in a quitline evaluation are more likely to be smokers - a drop-out and long-term follow-up study of the Swedish National Tobacco Quitline. *Tob Induc Dis* [Internet]. 2016;14:5. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/26843854>

24. Abrahamsen R, Svendsen MV, Henneberger PK, Gundersen GF, Torén K, Kongerud J, et al. Non-response in a cross-sectional study of respiratory health in Norway. *BMJ Open* [Internet]. 2016;6:e009912. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/26739738>


25. Oleske DM, Kwasny MM, Lavender SA, Andersson GBJ. Participation in occupational health longitudinal studies: predictors of missed visits and dropouts. *Ann Epidemiol* [Internet]. 2007;17:9–18. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/17140810>

- 1
2
3
4 483 26. Chatfield MD, Brayne CE, Matthews FE. A systematic literature review of attrition between
5
6
7 484 waves in longitudinal studies in the elderly shows a consistent pattern of dropout between
8
9 485 differing studies. J Clin Epidemiol [Internet]. 2005 [cited 2014 Mar 13];58:13–9. Available from:
10
11
12 486 <http://www.ncbi.nlm.nih.gov/pubmed/15649666>
13
14 487 27. Rotnitzky A, Robins J. Analysis of semi-parametric regression models with non-ignorable non-
15
16
17 488 response. Stat Med [Internet]. 16:81–102. Available from:
18
19 489 <http://www.ncbi.nlm.nih.gov/pubmed/9004385>
20
21
22 490
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19 Allocation
20
21
22
23
24
25
26
27
28 First
29 round
30
31
32
33
34
35
36
37 Second
38 round
39
40
41
42
43
44
45
46
47 Third
48 round
49
50
51
52
53
54
55
56
57 Fourth
58 round
59
60
Fifth
round



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	1
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	2-4
Objectives	3	State specific objectives, including any prespecified hypotheses	4
Methods			
Study design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5
Participants	6	(a) Cohort study—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up Case-control study—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls Cross-sectional study—Give the eligibility criteria, and the sources and methods of selection of participants	6
		(b) Cohort study—For matched studies, give matching criteria and number of exposed and unexposed Case-control study—For matched studies, give matching criteria and the number of controls per case	Not applicable
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6 and 7
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	
Bias	9	Describe any efforts to address potential sources of bias	
Study size	10	Explain how the study size was arrived at	Not applicable
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6-8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	7-8
		(b) Describe any methods used to examine subgroups and interactions	7
		(c) Explain how missing data were addressed	Not applicable
		(d) Cohort study—If applicable, explain how loss to follow-up was addressed Case-control study—If applicable, explain how matching of cases and controls was addressed	Not applicable

Cross-sectional study—If applicable, describe analytical methods taking account of sampling strategy
(e) Describe any sensitivity analyses

Continued on next page

For peer review only

Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Fig.1
		(b) Give reasons for non-participation at each stage	Fig.2
		(c) Consider use of a flow diagram	Fig.2
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	7
		(b) Indicate number of participants with missing data for each variable of interest	Table 1
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	N/A
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	Table 2-4
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Table 2-4
		(b) Report category boundaries when continuous variables were categorized	N/A
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	N/A
Discussion			
Key results	18	Summarise key results with reference to study objectives	9
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	10
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	10
Generalisability	21	Discuss the generalisability (external validity) of the study results	11-12
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	13

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Did psychosocial status, sociodemographics and smoking status affect non-attendance in control participants in the Danish Lung Cancer Screening Trial? A nested observational study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-030871.R1
Article Type:	Original research
Date Submitted by the Author:	28-Jun-2019
Complete List of Authors:	Malmqvist, Jessica; University of Copenhagen, Department of Public Health Siersma, Volkert; University of Copenhagen, Department of Public Health, the Research Unit for General Practice Thorsen, Hanne; University of Copenhagen, Department of Public Health, the Research Unit for General Practice Heleno, B; Universidade Nova de Lisboa, Rasmussen, Jakob; University of Copenhagen, Department of Public Health, the Research Unit for General Practice Brodersen, John; University of Copenhagen, Centre of Research & Education in General Practice Primary Health Care Research Unit, Zealand Region
Primary Subject Heading:	Public health
Secondary Subject Heading:	Research methods, General practice / Family practice
Keywords:	Bias, Mass screening, Lung neoplasms, Patient dropout

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Enseignement Supérieur (ABES).

Did psychosocial status, sociodemographics and smoking status affect non-attendance in control participants in the Danish Lung Cancer Screening Trial? A nested observational study

Jessica Malmqvist^{ac}, Volkert Siersma^a, Hanne Thorsen^a, Bruno Heleno^b Jakob Fraes Rasmussen^a, John Brodersen^{ac}

^a The Section of General Practice and Research Unit for General Practice, University of Copenhagen, Øster Farimagsgade 5, 24Q, 1014 Copenhagen, Denmark.

^b CEDOC, Chronic Diseases Research Centre, NOVA Medical School/Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, Campo dos Mártires da Pátria, 130, 1169-056 Lisbon, Portugal

^c The Primary Health Care Research Unit, Region Zealand, Denmark

Corresponding author:

Jessica Malmqvist

jessica.malmqvist@sund.ku.dk

Phone number: +45-35332583

Fax number: +45-35327946

Keywords

bias, mass screening, lung neoplasms, patient dropouts

Word count 2780

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Objectives: We investigated if psychosocial status, socio-demographics and smoking status affected non-attendance in the control group in the randomized Danish Lung Cancer Screening Trial (DLCST).

Design & setting: This study was an observational study nested in the DLCST. Due to large non-attendance in the control group in the second screening round we made an additional effort to collect questionnaire data from non-attenders in this group in the third screening round. We used a condition-specific questionnaire to assess psychosocial status. We analysed the differences in psychosocial status in the third and preceding rounds between non-attenders and attenders in the control group in multivariable linear regression models adjusted for socio-demographics and smoking status reported at baseline. Differences in socio-demographics and smoking status were analysed with chi-squared tests (categorical variables) and t-tests (continuous variables).

Primary outcome measure: Primary outcome was psychosocial status.

Participants: All control persons participating in the third screening round in the DLCST were included.

Results: Non-attenders in the third round had significantly worse psychosocial status than attenders in the scales: “Behaviour” 0.77 (99% CI 0.18;1.36), “Self-blame” 0.59 (99% CI 0.14;1.04), “Focus on airway symptoms” 0.22 (99% CI 0.08;0.36), “Stigmatisation” 0.51 (99% CI 0.16;0.86), “Introvert” 0.56 (99% CI 0.23;0.89), and “Harms of smoking” 0.35 (99% CI 0.11;0.59). Moreover, non-attenders had worse scores than attendees in the preceding screening rounds. Non-attenders also reported worse socio-demographics at baseline.

Conclusions: Non-attenders had a significantly worse psychosocial status and worse socio-demographics compared with attenders. The results of our study contribute with evidence of non-

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES)

response and attrition driven by psychosocial status, which in turn may be influenced by the screening intervention itself. This can be used to adjust cancer screening trial results for bias due to differential non-attendance.

Trial registration: The trial is registered in [Clinicaltrials.gov](https://clinicaltrials.gov) Protocol Registration System (identification no. [NCT00496977](https://clinicaltrials.gov/ct2/show/study/NCT00496977))

Article summary

Strengths and limitations

- Use of a condition-specific questionnaire with adequate psychometric properties ensured valid measures.
- Patient-reported data on non-respondents gave valuable empirical insight in drivers for non-attendance.
- Testing a previously hypothesized model for non-attendance empirically is another strength of the study.
- No comparison between non-attenders in the intervention and the control group was performed.
- No longer-term follow up on non-attenders was performed.

Introduction

Non-attendance may affect trial results and introduce bias in randomized controlled trials (RCTs).[1,2] Non-attendance reduces the power of the trial and, if non-attendance differs between the randomized groups, conventional effect estimates can be biased.[2] While we cannot change

1
2
3
4 66 the loss of power, we may remove bias due to differential non-attendance if we know and have
5
6
7 67 measured the factors that cause this non-attendance.[3] For some outcome measures, such as
8
9 68 disease incidence or mortality, non-attendance can be partially addressed if data can be obtained
10
11
12 69 from national electronic registers. However, non-attendance will be larger for outcome measures
13
14 70 that depend on direct data collection such as clinical measurements and patient reported
15
16 71 outcome measures (PROMs). Moreover, the factors driving non-attendance for these measures
17
18
19 72 may be very heterogeneous and may also be driven by the experiences of the trial participants in
20
21 73 the trial process.
22
23
24 74 The problems with differential non-attendance may be aggravated in trials assessing psychosocial
25
26 75 consequences of cancer screening as well as other interventions where it is impossible to blind
27
28
29 76 participants to allocation. Notably, a control group not offered screening may be less inclined to
30
31 77 return questionnaires enquiring into their experiences with a potentially beneficial intervention
32
33
34 78 they did not receive. Despite these potential problems, few lung cancer screening RCTs have
35
36 79 reported on non-attendance in both study groups let alone adjusted for potential differential non-
37
38
39 80 attendance.[4–7] The trials that do, seldom report on the factors involved in non-attendance.
40
41 81 Since cancer screening trials are investigating potentially life-threatening diseases there may be
42
43 82 emotional drivers of non-attendance, not typical for trials in general. Hence, it is of interest to
44
45
46 83 know which factors drive non-attendance in PROMs in cancer screening trials as this data is to be
47
48 84 collected in these trials and then used in adjusting for differential non-attendance.
49
50
51 85
52
53 86 The Danish Lung Cancer Screening Trial (DLCST) was an RCT including five annual screening rounds
54
55 87 of low-dose chest computed tomography (CT) plus clinical examinations in the intervention group
56
57
58 88 compared with annual clinical examinations only in the control group.[8] Furthermore, all the
59
60

participants were asked to complete a condition-specific questionnaire, measuring psychosocial consequences of lung cancer screening at these annual clinical assessments.[9] The results showed that people experienced negative psychosocial consequences merely by participating in the trial, and that negative consequences were higher for participants allocated to the control group.[7,10] A large number of control persons did not attend the second annual examination (n=513, 26.1%) while the non-attendance rate in the intervention group was low (n=71, 3.5%) (Fig. 1). To adjust for this differential non-attendance, inverse probability weighting was used.[7] In this method the observed outcomes are weighted with the inverse of the probability of being non-missing.[3] We hypothesised that these probabilities were adequately estimated from socio-demographic profile including smoking status, randomization group and psychosocial status in previous rounds.[7,11–13]

If these hypotheses were confirmed, then these factors would explain the witnessed difference in attendance between the trial groups and could be used to render them comparable. Analysed without such adjustments the assessment of the trial groups, and thereby the means of the scores from the responses to the questionnaire from the remaining trial participants would no longer be comparable.[14] Hence, the assessment of psychosocial harms of lung cancer screening could be biased.

Therefore, the overall aim of this study was to empirically assess whether control participants who did not attend the annual clinical examination had different psychosocial profiles compared with control participants who attended the annual clinical examination.

Materials and methods

Study design and population

1
2
3
4 112 The design and study population of DLCST have been described in detail previously.[7,8] Briefly,
5
6
7 113 the DLCST was an RCT, conducted at the Copenhagen University hospital Gentofte in Denmark
8
9 114 from October 2004 to March 2010. Heavy current and former smokers (at least 20 pack-years),
10
11
12 115 aged 50-70 years old, were randomized to either five rounds of screening with low-dose CT-scans
13
14 116 including clinical examinations (n=2052) or five clinical examinations only (n=2052). In the
15
16 117 enrolment visit, participants provided socio-demographic data, lifestyle and health information
17
18
19 118 (including smoking status), completed a questionnaire on their psychosocial status and underwent
20
21 119 spirometry. Participants randomized to screening also had a low-dose chest CT-scan within one
22
23
24 120 month of randomisation. In the following screening rounds, participants in the screened and
25
26 121 control groups were invited to a visit in the screening clinic where lung function tests were
27
28
29 122 performed, and questionnaires concerning health, lifestyle, smoking habits and psychosocial
30
31 123 status were completed and lung function tests were performed. Participants randomized to
32
33
34 124 screening also received a low-dose chest CT-scan.
35
36 125 This study is an observational study nested in the DLCST. During the second screening round, the
37
38 126 steering committee noted that a large number of control participants did not attend the screening
39
40
41 127 clinic visit when compared with the number of screened participants. Thus, the committee
42
43 128 decided to make additional efforts to collect questionnaire data for non-attenders in the control
44
45
46 129 group in the third screening round to perform post hoc analyses on whether psychosocial status
47
48 130 was an influencing factor (*Fig.2*).
49
50
51 131 During the third round, participants in the control group who did not attend the annual
52
53 132 examination were contacted by phone and part 1 of the questionnaire was sent with a postage
54
55
56 133 paid envelope to those who gave their oral consent. The data was used to supplement the data
57
58
59
60

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES)

collected on site at the screening clinic.[7] This yielded three groups within the control group, denoting the extent of response to the clinical examination and the questionnaire defined as:

1. *Attendees*: participants who attended the third screening round.

2. *Non-attendees*:

a) *Respondents*: participants who did not attend the annual examination but completed and returned the COS-LC after the phone interview.

b) *Non-respondents*: participants who did not attend the annual examination and did not complete the COS-LC.

Outcomes & Questionnaires

Primary outcome was psychosocial status measured with the Consequences Of Screening for Lung Cancer (COS-LC) questionnaire.[9] Part 1 of COS-LC comprised nine scales measuring various aspects of consequences of screening; a second part of COS-LC addressed the screening outcome and was therefore not applicable to the present analysis. Moreover, the primary part of COS-LC included four core scales: "Anxiety", "Behaviour", "Dejection" and "Sleep" that are not lung cancer specific. These scales have originally been developed from a breast cancer screening assessment instrument.[15] Additionally COS-LC comprised five lung cancer specific scales: "Self-blame", "Focus on airway symptoms", "Stigmatisation", "Introvert", and "Harm of smoking", which were developed from focus groups and other screening assessment instruments during the first DLCST screening round.[9,15] Therefore, only the core scales were used in the first round, while in the following four screening rounds both the core scales and the lung cancer specific scales were used to assess psychosocial status.[9]

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

157 **Statistics**

158 *Covariates*

159 Socio-demographic characteristics were defined by: social class (I highest social class to V lowest

160 social class), school and vocational education (from 9 years of elementary school to a university

161 education), employment status, living alone, smoking status (current or former smoker), smoking

162 history (pack-years), motivation for smoking cessation (from very strong to no wish to quit) and

163 Charlson Comorbidity Index (CCI). Furthermore, we adjusted for region of residence (Denmark is

164 divided into five health-administrative regions).

166 *Statistical analyses*

167 We performed three different analyses:

168 1. Analyses of differences in psychosocial status in the **third** round between *Attend*ers and

169 *Non-attenders-respondents*.

170 2. Analyses of differences in psychosocial status in the **second** round between *Attend*ers,

171 *Non-attenders-respondents* and *Non-attenders-non-respondents*.

172 3. Analyses of differences in psychosocial status in the **first** round, between *Attend*ers, *Non-*

173 *attenders-respondents* and *Non-attenders-non-respondents*.

174 Covariates at the first screening round were compared between *Attend*ers and *Non-attenders* by

175 chi-squared tests (categorical characteristics) and t-tests (continuous characteristics). Analyses of

176 psychosocial status at various points in the follow-up were performed in linear regression models

177 both unadjusted and in multivariable models adjusted for sex, age, region of residence, social

178 class, living alone, smoking status, pack years, motivation for smoking cessation and CCI. To adjust

for multiple testing a p-value <0.01 was considered statistically significant. All analyses were performed with SAS 9.4 (SAS Institute, Inc., Cary, NC).

Patient and Public Involvement

Patients and public were not involved in the design of the study.

Results

The inclusion process and participation rate of the DLCST are illustrated in Figure 1. The participation rate in the control group fell from 73.9% in the second round to 57.5% in the fourth round. The participation rate increased in the fifth, final, round (68.9%).

Figure 2 depicts the inclusion process of the present study and showed a dropout rate of 29.6% (n=607) in the third screening round with a higher distribution of *Non-attenders-non-respondents* (16.9% n=347) compared with *Non-attenders-respondents* (12.7% n=260).

In the first screening round we compared differences in socio-demographic characteristics in the two overarching groups (*Attenders, Non-attenders*) (Table 1).

Table 1, Socio-demographics

	Missing observations, total	Attendees n=1388	Non-attendees n=607	p-value
Covariates	n	n (%)**	n(%)**	
Sex	0			0.0963
Male		773 (55.7)	313 (51.6)	
Female		615 (44.3)	294 (48.4)	
Age, mean (SD)	0	57.4 (4.7)	56.9 (4.9)	0.0538
Social class	12			0.0079
I (highest social status)		103 (7.5)	35 (5.8)	
II		296 (21.4)	100 (16.6)	
III		256 (18.5)	114 (18.9)	
IV		375 (27.2)	161 (26.7)	
V (lowest social status)		168 (12.2)	107 (17.7)	
Employed, social class uncertain		112 (8.1)	49 (8.1)	
Outside the labour market		70 (5.1)	37 (6.1)	
School education	5			0.7765
9 years of elementary school		473 (34.2)	220 (36.3)	
10 years of elementary school		541 (39.1)	231 (38.1)	
3 years of upper secondary school		363 (26.2)	153 (25.3)	
Other		7 (0.5)	2 (0.3)	
Vocational education	4			0.1267
None		124 (9.0)	72 (11.9)	
Semi-skilled worker		17 (1.2)	10 (1.7)	
Vocational training		491 (35.4)	212 (35.0)	
Short further education		142 (10.2)	48 (7.9)	
Middle range training		357 (25.8)	167 (27.6)	
Long further education		153 (11.0)	64 (10.6)	
Other		102 (7.4)	32 (5.3)	
Employment status	6			0.8394
Employed		901 (65.2)	387 (63.9)	
Studying		8 (0.6)	4 (0.7)	
Job seeking		67 (4.8)	35 (5.8)	
Retired		407 (29.4)	180 (29.7)	
CCI, mean (SD)		0.26 (0.73)	0.31 (0.83)	0.0062
Living alone	17			0.0057
No		1011 (73.5)	405 (67.3)	
Yes		365 (26.5)	197 (32.7)	

Smoking status	0			0.0122
Current smoker		1046 (75.4)	489 (80.6)	
Former smoker		342 (24.6)	118 (19.4)	
Pack-years, <i>mean (SD)</i>	4	35.7 (13.7)	35.8 (12.3)	0.4207
Motivation for smoking cessation	30			0.0540
Very strong		141 (10.3)	74 (12.4)	
Strong		324 (23.7)	166 (27.8)	
Weak		331 (24.2)	144 (24.8)	
Very weak		116 (8.5)	42 (7.0)	
No wish to quit		113 (8.3)	54 (9.0)	
Current non-smoker		342 (25.0)	118 (19.7)	

**Except when indicated in the leftmost column that the mean and standard deviation (SD) are listed

There was a significant difference between the study groups for social class with more *Non-attenders* in the lowest social class (V) and a greater number of *Attenders* in the highest social classes (I-II).

Moreover, *Non-attenders* had a significantly higher CCI score indicating that they had more severe or a greater number of co-occurring conditions than *Attenders*. They were also to a greater extent living alone. Furthermore, a non-statistically significant trend of more current smokers with a higher wish of smoking cessation were seen among *Non-attenders*.

The results of the third screening round are listed in Table 2.

Table 2, Differences in psychosocial status in the third screening round

	Range of values	Responding rate per item n/n	Attenders n=1388 mean (SD)	Non-attenders-respondents n=260 mean (SD)	p-value	Difference in scores between the two groups mean (99%CI) ^a	p-value adjusted
COS-scales							
Anxiety	0-18	1349/249	1.7 (2.8)	2.1 (3.2)	0.0441	0.38 (-0.13;0.89)	0.0548
Behaviour	0-21	1343/246	2.1 (3.1)	2.9 (3.8)	<0.001	0.77 (0.18;1.36)	<0.001
Dejection	0-18	1354/255	1.9 (3.0)	2.4 (3.5)	0.013	0.49 (-0.06;1.04)	0.0225
Sleep	0-12	1357/252	1.9 (2.6)	2.3 (3.0)	0.041	0.35 (-0.12;0.82)	0.0599
COS-LC scales							
Self-blame	0-15	1356/234	2.2 (2.8)	3.1 (3.8)	<0.001	0.59 (0.14;1.04)	<0.001
Focus on airway symptoms	0-24	1363/239	0.3 (0.8)	0.6 (1.0)	<0.001	0.22 (0.08;0.36)	<0.001
Stigmatisation	0-12	1361/241	1.5 (1.9)	2.1 (2.4)	<0.001	0.51 (0.16;0.86)	<0.001
Introvert	0-18	1361/243	1.3 (1.8)	1.8 (2.2)	<0.001	0.56 (0.23;0.89)	<0.001
Harms of smoking	0-6	1356/248	0.9 (1.2)	1.3 (1.6)	<0.001	0.35 (0.11;0.59)	<0.001

^a) A positive value of the difference indicates that the persons that were interviewed by phone and later returned COS-LC had on average higher scores, i.e. more negative outcomes (e.g. higher anxiety) than the persons that showed up and completed the COS-LC on site. The differences are adjusted for sex, age, region of residence, social group, living alone, smoking status, pack years, motivation for smoking cessation and CCI. The continuous values variables (age and pack years) are included as a quadratic function as to allow for possible nonlinear effects.

In the core questionnaire COS (Consequences of Screening), *Non-attenders-respondents* had a statistically significant higher (worse) score than *Attenders* in the scale “Behaviour”. This effect was still present when adjusting for covariates. Moreover, there was a non-significant trend of worse scores in all COS scales among *Non-attenders-respondents*. In the lung cancer specific part

of the COS-LC, *Non-attenders-respondents* had statistically significantly higher scores in all scales both crude and adjusted.

Table 3 shows differences in psychosocial status between all three subgroups in the second screening round.

Table 3, Differences in psychosocial status in the second screening round

	Range of values	Responding rate per item n/n/n	Attenders n=1388	Non- attenders- respondent s n=260	Non- attenders- non- respondents n=347	p-value	p-value adjusted ^a
COS scales, mean (SD)							
Anxiety	0-18	1201/117/89	1.6 (2.7)	2.0 (3.0)	2.6 (3.8)	0.003	0.018
Behaviour	0-21	1195/114/88	1.9 (2.9)	2.4 (3.3)	2.8 (4.0)	0.012	0.071
Dejection	0-18	1217/117/87	1.8 (2.8)	2.3 (3.3)	3.0 (4.0)	<0.001	<0.001
Sleep	0-12	1220/116/88	1.7 (2.5)	2.3 (2.9)	2.6 (3.2)	<0.001	0.002
COS-LC scales, mean (SD)							
Self-blame	0-15	1210/118/88	1.7 (2.3)	2.1 (2.4)	2.6 (3.0)	<0.001	0.005
Focus on airway symptoms	0-24	1226/118/90	0.4 (0.8)	0.4 (0.8)	0.5 (0.9)	0.408	0.579
Stigmatisation	0-12	1225/121/90	1.5 (1.9)	1.8 (2.1)	2.1 (2.4)	0.028	0.146
Introvert	0-18	1223/116/90	1.3 (1.8)	1.8 (2.0)	1.4 (1.8)	0.012	0.021
Harms of smoking	0-6	1232/118/89	1.1 (1.3)	1.3 (1.3)	1.2 (1.4)	0.134	0.422

^a) A test for differences between the three groups adjusted for sex, age, region of residence, social group, living alone, smoking status, pack years, motivation for smoking cessation and the CCI. The continuous values variables (age and pack years) are included as a quadratic function as to allow for possible nonlinear effects.

Non-attenders had significantly worse crude scores compared with *Attenders* in all but one scale (“Behaviour”) in the COS scales. When adjusting for covariates the difference in scores was still significant in two scales “Dejection” and “Sleep”. In the lung cancer specific part, the crude and adjusted “Self-blame”-scale score was significantly worse for *Non-attenders*.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES)

The differences in psychosocial status in the first screening round between *Attendees*, *Non-attenders-respondents* and *Non-attenders-non-responders* showed a statistically significant worse unadjusted score in all but one COS-scale (“Behaviour”), for the two *Non-attenders* subgroups (Table 4). That effect disappeared in all but one scale, “Anxiety” when adjusting for covariates.

Table 4, Differences in psychosocial status in the first screening round

	Range of values	Responding rate per item n/n/n	Attendees n=1388 mean (SD)	Non-attenders-respondents n=260 mean (SD)	Non-attenders-non-respondents n=347 mean (SD)	p-value	p-value adjusted ^a
COS-scales							
Anxiety	0-18	1353/253/334	1.46 (2.16)	1.75 (2.54)	2.11 (2.66)	<0.001	0.0028
Behaviour	0-21	1365/257/340	0.75 (1.89)	1.05 (2.44)	1.04 (2.43)	0.0134	0.0976
Dejection	0-18	1372/257/339	1.25 (2.05)	1.54 (2.48)	1.68 (2.33)	0.0018	0.0512
Sleep	0-12	1368/253/344	0.62 (1.64)	0.86 (1.98)	0.90 (1.86)	0.0072	0.0530

^a) The differences are adjusted for sex, age, region of residence, social group, living alone, smoking status, pack years, motivation for smoking cessation and CCI. The continuous values variables (age and pack years) are included as a quadratic function as to allow for possible nonlinear effects.

Discussion

The present study showed considerable non-attendance in the control group of the DLCST. Data in the control group was not missing at random. Non-attenders had less favourable baseline socio-demographic profile when compared with attendees. More importantly, individuals who did not attend their annual clinical work-up had worse psychosocial status than the individuals who attended the clinic in the previous rounds. This can be used to adjust for differential non-attendance. Furthermore, these individuals also had worse psychosocial status during their missed round (assessed in the present study in the third round). This cannot be used to adjust differential non-attendance because this information is generally not available but proves the concept.

The use of a condition-specific questionnaire is a strength of the study. Previous research has demonstrated that condition-specific questionnaires are superior to generic questionnaires when measuring psychosocial consequences in cancer screening settings.[16] Furthermore, we used an appropriate longitudinal design i.e. we collected data at the same timepoints for both *Attendees* and *Non-attendees* at various times in the study, as well as we measured psychosocial status in both groups at baseline.[17] A limitation of the study is that we did not collect psychosocial outcomes of Non-attendees in the intervention group. This study was designed to gain knowledge of factors motivating such a large drop in participation in the control group. In hindsight, data on Non-attendees in the screened group could further help us understand the reasons for differential non-response.

In addition to the DLCST, two other trials assessed psychosocial consequences in lung cancer screening with low-dose CT.[6,18] Participants in the NELSON trial were invited to complete questionnaires at baseline and at the second round of screening (two years after baseline screening). Participants in the UKLS completed a questionnaire at baseline, two weeks after randomisation/CT-scan and 10-29 months after baseline. Unlike the DLCST, in these two trials the control group were not invited to an annual visit at the screening clinic. Although there were some differences in study design, non-response rates in the control groups in these three trials were similar and in all three trials there was differential non-response between the intervention and control group. Differences between attendees and non-attendees were reported in the UKLS trial. As in the DLCST, non-attendees had worse socio-demographic profile i.e. lower social class, and they were more likely single, younger and current smokers compared with attendees. However, these were pooled estimates for both the screening group and the control group.

1
2
3
4 331 In individuals diagnosed with cancer, anxiety and worse health-related quality of life have been
5
6
7 332 associated with dropout, which is consistent with our findings.[19] Since *Non-attenders* in our
8
9 333 study experienced a higher level of anxiety than *Attenders* in the first screening round (i.e.
10
11
12 334 baseline), this could have been the motivation for attending the trial; to get reassured of being
13
14 335 healthy.[20] Therefore, randomization to the control group may have caused disappointment, but
15
16 336 also attention drawn to not being part of a possibly beneficial intervention.[21] For example, the
17
18
19 337 secretary in the screening clinic received calls from participants randomized to the control group
20
21 338 expressing their disappointment of not being screened. Furthermore, the trial put focus on the
22
23
24 339 harms of smoking, which could have increased the anxiety and fear of disease in this subgroup
25
26 340 even more, which may have been a reason to subsequent non-attendance. Finally, missing data on
27
28
29 341 psychosocial status in a previous round may also have been a predictor for non-attendance in the
30
31 342 next screening round, which was not the scope for this study.
32
33
34 343 Low social status, younger age and current smoking status have previously been seen among
35
36 344 dropouts and non-respondents in lung health studies.[22–25] A systematic review reporting
37
38 345 dropout from longitudinal studies in elderly concluded that higher age and declining health were
39
40
41 346 high predictors of dropout. The latter is in agreement with our findings, although higher age is in
42
43 347 contrast to our findings.[26]
44
45
46 348
47
48 349 To our knowledge, this is the first cancer screening study testing hypotheses on reasons for
49
50
51 350 differential non-response empirically. The results of this study confirmed the hypotheses we made
52
53 351 in our previous study, using inverse probability weighting to adjust for differential non-
54
55
56 352 response.[3,7,27] More importantly, the results of the two other lung cancer screening trials
57
58
59
60

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES)

investigating dropout are consistent with ours. Hence, it is plausible that our results are generalisable to other cancer screening trials as well.

Therefore, future cancer screening trials should concurrently assess psychosocial status during the trial, not only to be able to assess the psychosocial effect of screening, but also to use this information to adjust any effect in the trial for bias due to differential non-attendance.

Conclusions

In conclusion, *Non-attenders* in the control group in the DLCST had a worse psychosocial status and a less favourable socio-demographic profile than *Attendees*.

The results of our study contribute with evidence of non-response driven by psychosocial status, which in turn may be influenced by the screening intervention itself. This can be used to adjust cancer screening trial results for bias due to differential attendance.

Abbreviations

RCT: Randomized controlled trial; PROM: Patient-reported outcome measure; CT: Computed tomography; DLCST: Danish Lung Cancer Screening Trial; COS-LC: Consequences of screening in lung cancer; COS: Consequences of screening; CCI: Charlson comorbidity index

Declarations

Ethics approval and consent to participate

The Ethical Committee of Copenhagen County approved the DLCST including this observational study nested in the DLCST on 31 January 2003: approval number KA-02045.

1
2
3
4 375 All participants signed an informed consent form and received an information letter about the
5
6
7 376 project and information about the ethical approval and data protection agency approval. The trial
8
9 377 is registered in [Clinicaltrials.gov](https://clinicaltrials.gov) Protocol Registration System (identification no. [NCT00496977](https://clinicaltrials.gov/ct2/show/study?term=NCT00496977))
10
11
12 378

13
14 379 **Availability of data and materials**

15
16 380 The corresponding author can provide the questionnaires and datasets generated and analysed
17
18
19 381 during the study on reasonable request.
20
21 382

22
23
24 383 **Competing interests**

25
26 384 None declared.
27
28
29 385

30
31 386 **Funding**

32
33 387 This work was supported by the Danish Ministry of Interior and Health, grant number [0900814](#).
34
35
36 388 The funding source had no role in study design, data collection and analysis, decision to publish, or
37
38
39 389 preparation of the manuscript.
40
41 390
42

43 391 **Author contributions**

44
45 392 JB and HT developed and designed the study. JB, HT and the DLCST staff collected data. VS
46
47
48 393 performed the statistical analyses. JM drafted the manuscript. JB, HT, BH, JFR, and VS all
49
50
51 394 contributed to parts of the manuscript as well as revisions of the manuscript. All authors approved
52
53 395 the final version of the manuscript, and no editorial assistance was received. All authors had full
54
55
56 396 access to all data in the study and are responsible of data retention and the accuracy of the data
57
58 397 analysis. JM and JB are guarantors of the study.
59
60

Acknowledgement

We wish to thank data manager Willy Karlslund for his contribution to generation of the databases and we also wish to thank the DLCST steering committee.

Fig.1 Flowchart, DLCST

Fig.2 Flowchart, present study

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Tierney JF. Investigating patient exclusion bias in meta-analysis. *Int J Epidemiol* [Internet]. 2004;34:79–87. Available from: <https://academic.oup.com/ije/article-lookup/doi/10.1093/ije/dyh300>

2. Zhang Y, Alyass A, Vanniyasingam T, Sadeghirad B, Flórez ID, Pichika SC, et al. A systematic survey of the methods literature on the reporting quality and optimal methods of handling participants with missing outcome data for continuous outcomes in randomized controlled trials. *J Clin Epidemiol* [Internet]. 2017;88:67–80. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/28579378>

3. Dufouil C, Brayne C, Clayton D. Analysis of longitudinal studies with death and drop-out: a case study. *Stat Med* [Internet]. 2004;23:2215–26. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/15236426>

4. Humphrey LL, Deffebach M, Pappas M, Baumann C, Artis K, Mitchell JP, et al. Screening for lung cancer with low-dose computed tomography: a systematic review to update the US Preventive services task force recommendation. *Ann Intern Med* [Internet]. 2013 [cited 2014 Feb 26];159:411–20. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/23897166>

5. Wu GX, Raz DJ, Brown L, Sun V. Psychological Burden Associated With Lung Cancer Screening: A Systematic Review. *Clin Lung Cancer* [Internet]. 2016;17:315–24. Available from: <http://linkinghub.elsevier.com/retrieve/pii/S1525730416300535>

6. Brain K, Lifford KJ, Carter B, Burke O, McDonald F, Devaraj A, et al. Long-term psychosocial outcomes of low-dose CT screening: results of the UK Lung Cancer Screening randomised controlled trial. *Thorax* [Internet]. 2016;71:996–1005. Available from:

<http://thorax.bmj.com/lookup/doi/10.1136/thoraxjnl-2016-208283>

7. Rasmussen JF, Siersma V, Pedersen JH, Brodersen J. Psychosocial consequences in the Danish randomised controlled lung cancer screening trial (DLCST). *Lung Cancer* [Internet]. 2015;87:65–72. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/25433982>

8. Pedersen JH, Ashraf H, Dirksen A, Bach K, Hansen H, Toennesen P, et al. The Danish randomized lung cancer CT screening trial--overall design and results of the prevalence round. *J Thorac Oncol* [Internet]. 2009 [cited 2013 Sep 18];4:608–14. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/19357536>

9. Brodersen J, Thorsen H, Kreiner S. Consequences of screening in lung cancer: development and dimensionality of a questionnaire. *Value Health* [Internet]. 2010 [cited 2013 Oct 1];13:601–12. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/20345552>

10. Aggestrup LM, Hestbech MS, Siersma V, Pedersen JH, Brodersen J. Psychosocial consequences of allocation to lung cancer screening: a randomised controlled trial. *BMJ Open* [Internet]. 2012 [cited 2013 Oct 1];2:e000663. Available from: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3293139&tool=pmcentrez&rendertype=abstract>

11. Heydarpour B, Saeidi M, Ezzati P, Soroush A, Komasi S. Sociodemographic Predictors in Failure to Complete Outpatient Cardiac Rehabilitation. *Ann Rehabil Med* [Internet]. 2015;39:863–71. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/26798599>

12. de Graaf R, van Dorsselaer S, Tuithof M, ten Have M. Sociodemographic and psychiatric predictors of attrition in a prospective psychiatric epidemiological study among the general population. Result of the Netherlands Mental Health Survey and Incidence Study-2. *Compr*

1
2
3
4 450 Psychiatry [Internet]. 2013;54:1131–9. Available from:
5
6
7 451 <http://linkinghub.elsevier.com/retrieve/pii/S0010440X13001284>
8
9
10 452 13. Field JK, Duffy SW, Baldwin DR, Whynes DK, Devaraj A, Brain KE, et al. UK Lung Cancer RCT Pilot
11
12 453 Screening Trial: baseline findings from the screening arm provide evidence for the potential
13
14 454 implementation of lung cancer screening. Thorax [Internet]. 2015;1–10. Available from:
15
16
17 455 <http://www.ncbi.nlm.nih.gov/pubmed/26645413>
18
19
20 456 14. McCaffery KJ. Assessing psychosocial/quality of life outcomes in screening: how do we do it
21
22 457 better? J Epidemiol Community Heal [Internet]. 2004;58:968–70. Available from:
23
24
25 458 <http://jech.bmj.com/cgi/doi/10.1136/jech.2004.025114>
26
27
28 459 15. Brodersen J, Thorsen H. Consequences of Screening in Breast Cancer (COS-BC): development of
29
30 460 a questionnaire. Scand J Prim Health Care [Internet]. 2008 [cited 2013 Oct 1];26:251–6. Available
31
32 461 from:
33
34
35 462 <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3406644&tool=pmcentrez&renderty>
36
37 463 [pe=abstract](http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3406644&tool=pmcentrez&renderty)
38
39
40 464 16. Brodersen J, Thorsen H, Cockburn J. The adequacy of measurement of short and long-term
41
42 465 consequences of false-positive screening mammography. J Med Screen. 2004;11:39–44.
43
44
45 466 17. DeFrank JT, Barclay C, Sheridan S, Brewer NT, Gilliam M, Moon AM, et al. The psychological
46
47 467 harms of screening: the evidence we have versus the evidence we need. J Gen Intern Med
48
49 468 [Internet]. 2015;30:242–8. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/25150033>
50
51
52
53 469 18. van den Bergh KAM, Essink-Bot ML, Borsboom GJJM, Scholten ET, van Klaveren RJ, de Koning
54
55 470 HJ. Long-term effects of lung cancer computed tomography screening on health-related quality of
56
57 471 life: the NELSON trial. Eur Respir J [Internet]. 2011 [cited 2014 Oct 3];38:154–61. Available from:
58
59
60

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES)

- <http://www.ncbi.nlm.nih.gov/pubmed/21148229>
19. Mercieca-Bebber RL, Price MA, Bell ML, King MT, Webb PM, Butow PN, et al. Ovarian cancer study dropouts had worse health-related quality of life and psychosocial symptoms at baseline and over time. *Asia Pac J Clin Oncol* [Internet]. 2017;13:e381–8. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/27573704>
20. Østerø J, Siersma V, Brodersen J. Breast cancer screening implementation and reassurance. *Eur J Public Health*. 2014;24:258–63.
21. Wendler D, Krohmal B, Emanuel EJ, Grady C. Why patients continue to participate in clinical research. *Arch Intern Med* [Internet]. 2008 [cited 2013 Oct 1];168:1294–9. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/18574086>
22. Snow WM, Connett JE, Sharma S, Murray RP. Predictors of attendance and dropout at the Lung Health Study 11-year follow-up. *Contemp Clin Trials* [Internet]. 2007;28:25–32. Available from: <http://linkinghub.elsevier.com/retrieve/pii/S1551714406001157>
23. Nohlert E, Öhrvik J, Helgason ÁR. Non-responders in a quitline evaluation are more likely to be smokers - a drop-out and long-term follow-up study of the Swedish National Tobacco Quitline. *Tob Induc Dis* [Internet]. 2016;14:5. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/26843854>
24. Abrahamsen R, Svendsen MV, Henneberger PK, Gundersen GF, Torén K, Kongerud J, et al. Non-response in a cross-sectional study of respiratory health in Norway. *BMJ Open* [Internet]. 2016;6:e009912. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/26739738>
25. Oleske DM, Kwasny MM, Lavender SA, Andersson GBJ. Participation in occupational health longitudinal studies: predictors of missed visits and dropouts. *Ann Epidemiol* [Internet]. 2007;17:9–18. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/17140810>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

494 26. Chatfield MD, Brayne CE, Matthews FE. A systematic literature review of attrition between
495 waves in longitudinal studies in the elderly shows a consistent pattern of dropout between
496 differing studies. J Clin Epidemiol [Internet]. 2005 [cited 2014 Mar 13];58:13–9. Available from:
497 <http://www.ncbi.nlm.nih.gov/pubmed/15649666>

498 27. Rotnitzky A, Robins J. Analysis of semi-parametric regression models with non-ignorable non-
499 response. Stat Med [Internet]. 16:81–102. Available from:
500 <http://www.ncbi.nlm.nih.gov/pubmed/9004385>

501

Enseignement Supérieur (ABES) .
Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Allocation


First round


Second round

Third round

Fourth round

Fifth round





STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	1
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	2-4
Objectives	3	State specific objectives, including any prespecified hypotheses	4
Methods			
Study design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	6
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	Not applicable
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6 and 7
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	
Bias	9	Describe any efforts to address potential sources of bias	
Study size	10	Explain how the study size was arrived at	Not applicable
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6-8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	7-8
		(b) Describe any methods used to examine subgroups and interactions	7
		(c) Explain how missing data were addressed	Not applicable
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed	Not applicable

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Continued on next page

Cross-sectional study—If applicable, describe analytical methods taking account of sampling strategy
(e) Describe any sensitivity analyses

For peer review only

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES).

Results

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Fig.1
		(b) Give reasons for non-participation at each stage	Fig.2
		(c) Consider use of a flow diagram	Fig.2
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	7
		(b) Indicate number of participants with missing data for each variable of interest	Table 1
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	N/A
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	Table 2-4
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Table 2-4
		(b) Report category boundaries when continuous variables were categorized	N/A
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	N/A
Discussion			
Key results	18	Summarise key results with reference to study objectives	9
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	10
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	10
Generalisability	21	Discuss the generalisability (external validity) of the study results	11-12
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	13

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Did psychosocial status, sociodemographics and smoking status affect non-attendance in control participants in the Danish Lung Cancer Screening Trial? A nested observational study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-030871.R2
Article Type:	Original research
Date Submitted by the Author:	29-Oct-2019
Complete List of Authors:	Malmqvist, Jessica; University of Copenhagen, Department of Public Health Siersma, Volkert; University of Copenhagen, Department of Public Health, the Research Unit for General Practice Thorsen, Hanne; University of Copenhagen, Department of Public Health, the Research Unit for General Practice Heleno, B; Universidade Nova de Lisboa, Rasmussen, Jakob; University of Copenhagen, Department of Public Health, the Research Unit for General Practice Brodersen, John; University of Copenhagen, Centre of Research & Education in General Practice Primary Health Care Research Unit, Zealand Region
Primary Subject Heading:	Public health
Secondary Subject Heading:	Research methods, General practice / Family practice
Keywords:	Bias, Mass screening, Lung neoplasms, Patient dropout

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Enseignement Supérieur (ABES).

Did psychosocial status, sociodemographics and smoking status affect non-attendance in control participants in the Danish Lung Cancer Screening Trial? A nested observational study

Jessica Malmqvist^{ac}, Volkert Siersma^a, Hanne Thorsen^a, Bruno Heleno^b Jakob Fraes Rasmussen^a, John Brodersen^{ac}

^a The Section of General Practice and Research Unit for General Practice, University of Copenhagen, Øster Farimagsgade 5, 24Q, 1014 Copenhagen, Denmark.

^b CEDOC, Chronic Diseases Research Centre, NOVA Medical School/Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, Campo dos Mártires da Pátria, 130, 1169-056 Lisbon, Portugal

^c The Primary Health Care Research Unit, Region Zealand, Denmark

Corresponding author:

Jessica Malmqvist

jessica.malmqvist@sund.ku.dk

Phone number: +45-35332583

Fax number: +45-35327946

Keywords

bias, mass screening, lung neoplasms, patient dropouts

Word count 2780

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

21 **Abstract**

22 **Objectives:** We investigated if psychosocial status, socio-demographics and smoking status

23 affected non-attendance in the control group in the randomized Danish Lung Cancer Screening

24 Trial (DLCST).

25 **Design & setting:** This study was an observational study nested in the DLCST. Due to large non-

26 attendance in the control group in the second screening round we made an additional effort to

27 collect questionnaire data from non-attenders in this group in the third screening round. We used

28 a condition-specific questionnaire to assess psychosocial status. We analysed the differences in

29 psychosocial status in the third and preceding rounds between non-attenders and attenders in the

30 control group in multivariable linear regression models adjusted for socio-demographics and

31 smoking status reported at baseline. Differences in socio-demographics and smoking status were

32 analysed with chi-squared tests (categorical variables) and t-tests (continuous variables).

33 **Primary outcome measure:** Primary outcome was psychosocial status.

34 **Participants:** All control persons participating in the third screening round in the DLCST were

35 included.

36 **Results:** Non-attenders in the third round had significantly worse psychosocial status than

37 attenders in the scales: “Behaviour” 0.77 (99% CI 0.18;1.36), “Self-blame” 0.59 (99% CI 0.14;1.04),

38 “Focus on airway symptoms” 0.22 (99% CI 0.08;0.36), “Stigmatisation” 0.51 (99% CI 0.16;0.86),

39 “Introvert” 0.56 (99% CI 0.23;0.89), and “Harms of smoking” 0.35 (99% CI 0.11;0.59). Moreover,

40 non-attenders had worse scores than attendees in the preceding screening rounds. Non-attenders

41 also reported worse socio-demographics at baseline.

42 **Conclusions:** Non-attenders had a significantly worse psychosocial status and worse socio-

43 demographics compared with attenders. The results of our study contribute with evidence of non-

response and attrition driven by psychosocial status, which in turn may be influenced by the screening intervention itself. This can be used to adjust cancer screening trial results for bias due to differential non-attendance.

Trial registration: The trial is registered in [Clinicaltrials.gov](https://clinicaltrials.gov) Protocol Registration System (identification no. [NCT00496977](https://clinicaltrials.gov/ct2/show/study/NCT00496977))

Article summary

Strengths and limitations

- Use of a condition-specific questionnaire with adequate psychometric properties ensured valid measures.
- Patient-reported data on non-respondents gave valuable empirical insight in drivers for non-attendance.
- Testing a previously hypothesized model for non-attendance empirically is another strength of the study.
- No comparison between non-attenders in the intervention and the control group was performed.
- No longer-term follow up on non-attenders was performed.

Introduction

Non-attendance may affect trial results and introduce bias in randomized controlled trials (RCTs).(1,2) Non-attendance reduces the power of the trial and, if non-attendance differs between the randomized groups, conventional effect estimates can be biased.(2) While we cannot change

1
2
3
4 66 the loss of power, we may remove bias due to differential non-attendance if we know and have
5
6
7 67 measured the factors that cause this non-attendance.(3) For some outcome measures, such as
8
9 68 disease incidence or mortality, non-attendance can be partially addressed if data can be obtained
10
11
12 69 from national electronic registers. However, non-attendance will be larger for outcome measures
13
14 70 that depend on direct data collection such as clinical measurements and patient reported
15
16 71 outcome measures (PROMs). Moreover, the factors driving non-attendance for these measures
17
18
19 72 may be very heterogeneous and may also be driven by the experiences of the trial participants in
20
21 73 the trial process.
22
23
24 74 The problems with differential non-attendance may be aggravated in trials assessing psychosocial
25
26 75 consequences of cancer screening as well as other interventions where it is impossible to blind
27
28
29 76 participants to allocation. Notably, a control group not offered screening may be less inclined to
30
31 77 return questionnaires enquiring into their experiences with a potentially beneficial intervention
32
33
34 78 they did not receive. However, the psychosocial dimensions of non-attendance and potential
35
36 79 consequences of these in lung cancer screening trials are only partially researched.(4–7) Since
37
38
39 80 cancer screening trials are investigating potentially life-threatening diseases there may be
40
41 81 emotional drivers of non-attendance, not typical for trials in general. Hence, it is of interest to
42
43
44 82 know which factors drive non-attendance in PROMs in cancer screening trials as this data is to be
45
46 83 collected in these trials and then used in adjusting for differential non-attendance.
47
48 84
49
50
51 85 The Danish Lung Cancer Screening Trial (DLCST) was an RCT including five annual screening rounds
52
53 86 of low-dose chest computed tomography (CT) plus clinical examinations in the intervention group
54
55
56 87 compared with annual clinical examinations only in the control group.(8) Furthermore, all the
57
58 88 participants were asked to complete a condition-specific questionnaire, measuring psychosocial
59
60

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES)

consequences of lung cancer screening at these annual clinical assessments.(9) The results showed that people experienced negative psychosocial consequences merely by participating in the trial, and that negative consequences were higher for participants allocated to the control group.(7,10) A large number of control persons did not attend the second annual examination (n=513, 26.1%) while the non-attendance rate in the intervention group was low (n=71, 3.5%) (Fig. 1). To adjust for this differential non-attendance, inverse probability weighting was used.(7) In this method the observed outcomes are weighted with the inverse of the probability of being non missing.(3) We hypothesised that these probabilities were adequately estimated from socio-demographic profile including smoking status, randomization group and psychosocial status in previous rounds.(7,11–13)

If these hypotheses were confirmed, then these factors would explain the witnessed difference in attendance between the trial groups and could be used to render them comparable. Analysed without such adjustments the assessment of the trial groups, and thereby the means of the scores from the responses to the questionnaire from the remaining trial participants would no longer be comparable.(14) Hence, the assessment of psychosocial harms of lung cancer screening could be biased.

Therefore, the overall aim of this study was to empirically assess whether control participants who did not attend the annual clinical examination had different psychosocial profiles compared with control participants who attended the annual clinical examination.

Materials and methods

Study design and population

1
2
3
4 111 The design and study population of DLCST have been described in detail previously.(7,8) Briefly,
5
6
7 112 the DLCST was an RCT, conducted at the Copenhagen University hospital Gentofte in Denmark
8
9 113 from October 2004 to March 2010. Heavy current and former smokers (at least 20 pack-years),
10
11
12 114 aged 50-70 years old, were randomized to either five rounds of screening with low-dose CT-scans
13
14 115 including clinical examinations (n=2052) or five clinical examinations only (n=2052). In the
15
16 116 enrolment visit, participants provided socio-demographic data, lifestyle and health information
17
18
19 117 (including smoking status), completed a questionnaire on their psychosocial status and underwent
20
21
22 118 spirometry. Participants randomized to screening also had a low-dose chest CT-scan within one
23
24 119 month of randomisation. In the following screening rounds, participants in the screened and
25
26 120 control groups were invited to a visit in the screening clinic where lung function tests were
27
28
29 121 performed, and questionnaires concerning health, lifestyle, smoking habits and psychosocial
30
31 122 status were completed and lung function tests were performed. Participants randomized to
32
33
34 123 screening also received a low-dose chest CT-scan.
35
36 124 This study is an observational study nested in the DLCST. During the second screening round, the
37
38
39 125 steering committee noted that a large number of control participants did not attend the screening
40
41 126 clinic visit when compared with the number of screened participants. Thus, the committee
42
43
44 127 decided to make additional efforts to collect questionnaire data for non-attenders in the control
45
46 128 group in the third screening round to perform post hoc analyses on whether psychosocial status
47
48 129 was an influencing factor (*Fig.2*).
49
50
51 130 During the third round, participants in the control group who did not attend the annual
52
53 131 examination were contacted by phone and part 1 of the questionnaire was sent with a postage
54
55
56 132 paid envelope to those who gave their oral consent. The data was used to supplement the data
57
58
59
60

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES)

collected on site at the screening clinic.⁽⁷⁾ This yielded three groups within the control group, denoting the extent of response to the clinical examination and the questionnaire defined as:

1. *Attendees*: participants who attended the third screening round.

2. *Non-attendees*:

a) *Respondents*: participants who did not attend the annual examination but completed and returned the COS-LC after the phone interview.

b) *Non-respondents*: participants who did not attend the annual examination and did not complete the COS-LC.

Outcomes & Questionnaires

Primary outcome was psychosocial status measured with the Consequences Of Screening for Lung Cancer (COS-LC) questionnaire.⁽⁹⁾ Part 1 of COS-LC comprised nine scales measuring various aspects of consequences of screening; a second part of COS-LC addressed the screening outcome and was therefore not applicable to the present analysis. Moreover, the primary part of COS-LC included four core scales: "Anxiety", "Behaviour", "Dejection" and "Sleep" that are not lung cancer specific. These scales have originally been developed from a breast cancer screening assessment instrument.⁽¹⁵⁾ Additionally COS-LC comprised five lung cancer specific scales: "Self-blame", "Focus on airway symptoms", "Stigmatisation", "Introvert", and "Harm of smoking", which were developed from focus groups and other screening assessment instruments during the first DLCST screening round.^(9,15) Therefore, only the core scales were used in the first round, while in the following four screening rounds both the core scales and the lung cancer specific scales were used to assess psychosocial status.⁽⁹⁾

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

156 **Statistics**

157 *Covariates*

158 Socio-demographic characteristics were defined by: social class (I highest social class to V lowest

159 social class), school and vocational education (from 9 years of elementary school to a university

160 education), employment status, living alone, smoking status (current or former smoker), smoking

161 history (pack-years), motivation for smoking cessation (from very strong to no wish to quit) and

162 Charlson Comorbidity Index (CCI). Furthermore, we adjusted for region of residence (Denmark is

163 divided into five health-administrative regions).

164

165 *Statistical analyses*

166 We performed three different analyses:

167 1. Analyses of differences in psychosocial status in the **third** round between *Attend*ers and

168 *Non-attenders-respondents*.

169 2. Analyses of differences in psychosocial status in the **second** round between *Attend*ers,

170 *Non-attenders-respondents* and *Non-attenders-non-respondents*.

171 3. Analyses of differences in psychosocial status in the **first** round, between *Attend*ers, *Non-*

172 *attenders-respondents* and *Non-attenders-non-respondents*.

173 Covariates at the first screening round were compared between *Attend*ers and *Non-attenders* by

174 chi-squared tests (categorical characteristics) and t-tests (continuous characteristics). Analyses of

175 psychosocial status at various points in the follow-up were performed in linear regression models

176 both unadjusted and in multivariable models adjusted for sex, age, region of residence, social

177 class, living alone, smoking status, pack years, motivation for smoking cessation and CCI. To adjust

for multiple testing we used the Benjamini-Hochberg procedure and the False Discovery Rate

(FDR) was set to 5% (16). All analyses were performed with SAS 9.4 (SAS Institute, Inc., Cary, NC).

Patient and Public Involvement

Patients and public were not involved in the design of the study.

Results

The inclusion process and participation rate of the DLCST are illustrated in Figure 1. The participation rate in the control group fell from 73.9% in the second round to 57.5% in the fourth round. The participation rate increased in the fifth, final, round (68.9%).

Figure 2 depicts the inclusion process of the present study and showed a dropout rate of 29.6% (n=607) in the third screening round with a higher distribution of *Non-attenders-non-respondents* (16.9% n=347) compared with *Non-attenders-respondents* (12.7% n=260).

In the first screening round we compared differences in socio-demographic characteristics in the two overarching groups (*Attenders, Non-attenders*) (Table 1).

Table 1, Socio-demographics

	Missing observations, total	Attendees n=1388	Non-attendees n=607	p-value*
Covariates	n	n (%)**	n(%)**	
Sex	0			0.0963
Male		773 (55.7)	313 (51.6)	
Female		615 (44.3)	294 (48.4)	
Age, mean (SD)	0	57.4 (4.7)	56.9 (4.9)	0.0538
Social class	12			0.0079
I (highest social status)		103 (7.5)	35 (5.8)	
II		296 (21.4)	100 (16.6)	
III		256 (18.5)	114 (18.9)	
IV		375 (27.2)	161 (26.7)	
V (lowest social status)		168 (12.2)	107 (17.7)	
Employed, social class uncertain		112 (8.1)	49 (8.1)	
Outside the labour market		70 (5.1)	37 (6.1)	
School education	5			0.7765
9 years of elementary school		473 (34.2)	220 (36.3)	
10 years of elementary school		541 (39.1)	231 (38.1)	
3 years of upper secondary school		363 (26.2)	153 (25.3)	
Other		7 (0.5)	2 (0.3)	
Vocational education	4			0.1267
None		124 (9.0)	72 (11.9)	
Semi-skilled worker		17 (1.2)	10 (1.7)	
Vocational training		491 (35.4)	212 (35.0)	
Short further education		142 (10.2)	48 (7.9)	
Middle range training		357 (25.8)	167 (27.6)	
Long further education		153 (11.0)	64 (10.6)	
Other		102 (7.4)	32 (5.3)	
Employment status	6			0.8394
Employed		901 (65.2)	387 (63.9)	
Studying		8 (0.6)	4 (0.7)	
Job seeking		67 (4.8)	35 (5.8)	
Retired		407 (29.4)	180 (29.7)	
CCI, mean (SD)		0.26 (0.73)	0.31 (0.83)	0.0062
Living alone	17			0.0057
No		1011 (73.5)	405 (67.3)	
Yes		365 (26.5)	197 (32.7)	

Smoking status	0			0.0122
Current smoker		1046 (75.4)	489 (80.6)	
Former smoker		342 (24.6)	118 (19.4)	
Pack-years, <i>mean (SD)</i>	4	35.7 (13.7)	35.8 (12.3)	0.4207
Motivation for smoking cessation	30			0.0540
Very strong		141 (10.3)	74 (12.4)	
Strong		324 (23.7)	166 (27.8)	
Weak		331 (24.2)	144 (24.8)	
Very weak		116 (8.5)	42 (7.0)	
No wish to quit		113 (8.3)	54 (9.0)	
Current non-smoker		342 (25.0)	118 (19.7)	

* Benjamini-Hochberg rejects all p-values above 0.0321 to control the FDR at 0.05

**Except when indicated in the leftmost column that the mean and standard deviation (SD) are listed

There was a significant difference between the study groups for social class with more *Non-attenders* in the lowest social class (V) and a greater number of *Attenders* in the highest social classes (I-II).

Moreover, *Non-attenders* had a significantly higher CCI score indicating that they had more severe or a greater number of co-occurring conditions than *Attenders*. They were also to a greater extent living alone. Furthermore, there were significantly more current smokers and a non-significant trend of a higher wish to quit smoking in the group of *Non-attenders* compared with *Attenders*.

The results of the third screening round are listed in Table 2.

Table 2, Differences in psychosocial status in the third screening round

	Range of values	Responding rate per item n/n	Attenders n=1388 mean (SD)	Non-attenders-respondents n=260 mean (SD)	p-value*	Difference in scores between the two groups mean (99%CI) ^a	p-value adjusted*
COS-scales							
Anxiety	0-18	1349/249	1.7 (2.8)	2.1 (3.2)	0.0441	0.38 (-0.13;0.89)	0.0548
Behaviour	0-21	1343/246	2.1 (3.1)	2.9 (3.8)	<0.001	0.77 (0.18;1.36)	<0.001
Dejection	0-18	1354/255	1.9 (3.0)	2.4 (3.5)	0.013	0.49 (-0.06;1.04)	0.0225
Sleep	0-12	1357/252	1.9 (2.6)	2.3 (3.0)	0.041	0.35 (-0.12;0.82)	0.0599
COS-LC scales							
Self-blame	0-15	1356/234	2.2 (2.8)	3.1 (3.8)	<0.001	0.59 (0.14;1.04)	<0.001
Focus on airway symptoms	0-24	1363/239	0.3 (0.8)	0.6 (1.0)	<0.001	0.22 (0.08;0.36)	<0.001
Stigmatisation	0-12	1361/241	1.5 (1.9)	2.1 (2.4)	<0.001	0.51 (0.16;0.86)	<0.001
Introvert	0-18	1361/243	1.3 (1.8)	1.8 (2.2)	<0.001	0.56 (0.23;0.89)	<0.001
Harms of smoking	0-6	1356/248	0.9 (1.2)	1.3 (1.6)	<0.001	0.35 (0.11;0.59)	<0.001

^a) A positive value of the difference indicates that the persons that were interviewed by phone and later returned COS-LC had on average higher scores, i.e. more negative outcomes (e.g. higher anxiety) than the persons that showed up and completed the COS-LC on site. The differences are adjusted for sex, age, region of residence, social group, living alone, smoking status, pack years, motivation for smoking cessation and CCI. The continuous values variables (age and pack years) are included as a quadratic function as to allow for possible nonlinear effects.

* Benjamini-Hochberg rejects all p-values above 0.0321 to control the FDR at 0.05.

In the core questionnaire COS (Consequences of Screening), *Non-attenders-respondents* had a statistically significant higher (worse) score than *Attenders* in the scales “Behaviour” and “Dejection”. These effects were still present when adjusting for covariates. Moreover, there was a

non-significant trend of worse scores in all COS scales among *Non-attenders-respondents*. In the lung cancer specific part of the COS-LC, *Non-attenders-respondents* had statistically significantly higher scores in all scales both crude and adjusted.

Table 3 shows differences in psychosocial status between all three subgroups in the second screening round.

Table 3, Differences in psychosocial status in the second screening round

	Range of values	Responding rate per item n/n/n	Attenders n=1388	Non- attenders- respondent s n=260	Non- attenders- non- respondents n=347	p-value*	p-value adjusted*
COS scales, mean (SD)							
Anxiety	0-18	1201/117/89	1.6 (2.7)	2.0 (3.0)	2.6 (3.8)	0.003	0.018
Behaviour	0-21	1195/114/88	1.9 (2.9)	2.4 (3.3)	2.8 (4.0)	0.012	0.071
Dejection	0-18	1217/117/87	1.8 (2.8)	2.3 (3.3)	3.0 (4.0)	<0.001	<0.001
Sleep	0-12	1220/116/88	1.7 (2.5)	2.3 (2.9)	2.6 (3.2)	<0.001	0.002
COS-LC scales, mean (SD)							
Self-blame	0-15	1210/118/88	1.7 (2.3)	2.1 (2.4)	2.6 (3.0)	<0.001	0.005
Focus on airway symptoms	0-24	1226/118/90	0.4 (0.8)	0.4 (0.8)	0.5 (0.9)	0.408	0.579
Stigmatisation	0-12	1225/121/90	1.5 (1.9)	1.8 (2.1)	2.1 (2.4)	0.028	0.146
Introvert	0-18	1223/116/90	1.3 (1.8)	1.8 (2.0)	1.4 (1.8)	0.012	0.021
Harms of smoking	0-6	1232/118/89	1.1 (1.3)	1.3 (1.3)	1.2 (1.4)	0.134	0.422

^{a)} A test for differences between the three groups adjusted for sex, age, region of residence, social group, living alone, smoking status, pack years, motivation for smoking cessation and the CCI. The continuous values variables (age and pack years) are included as a quadratic function as to allow for possible nonlinear effects.

* Benjamini-Hochberg rejects all p-values above 0.0321 to control the FDR at 0.05.

Non-attenders had significantly worse crude scores compared with *Attenders* in all the COS scales.

When adjusting for covariates the difference in scores was still significant in the three scales

1
2
3
4 287 “Anxiety”, “Dejection” and “Sleep”. In the lung cancer specific part, the crude and adjusted “Self-
5
6
7 288 blame” and “Introvert”-scale scores were significantly worse for *Non-attenders*. The difference in
8
9 289 “Stigmatisation” scale score was statistically significant in the unadjusted analyses, but
10
11
12 290 disappeared in the adjusted analyses.
13
14 291 The differences in psychosocial status in the first screening round between *Attendees*, *Non-*
15
16 292 *attenders-respondents* and *Non-attenders-non-responders* showed a statistically significant worse
17
18
19 293 unadjusted score in all COS-scales, for the two *Non-attenders* subgroups (Table 4). That effect
20
21 294 disappeared in all but one scale, “Anxiety” when adjusting for covariates.
22
23
24 295
25 296

Table 4, Differences in psychosocial status in the first screening round

	Range of values	Responding rate per item n/n/n	Attendees n=1388 mean (SD)	Non-attenders-respondents n=260 mean (SD)	Non-attenders-non-respondents n=347 mean (SD)	p-value*	p-value adjusted ^a
COS-scales							
Anxiety	0-18	1353/253/334	1.46 (2.16)	1.75 (2.54)	2.11 (2.66)	<0.001	0.0028
Behaviour	0-21	1365/257/340	0.75 (1.89)	1.05 (2.44)	1.04 (2.43)	0.0134	0.0976
Dejection	0-18	1372/257/339	1.25 (2.05)	1.54 (2.48)	1.68 (2.33)	0.0018	0.0512
Sleep	0-12	1368/253/344	0.62 (1.64)	0.86 (1.98)	0.90 (1.86)	0.0072	0.0530

31
32
33
34 300
35
36 301
37
38 302
39 303 ^a) The differences are adjusted for sex, age, region of residence, social group, living alone, smoking status, pack years, motivation for smoking cessation
40 304 and CCI. The continuous values variables (age and pack years) are included as a quadratic function as to allow for possible nonlinear effects.
41 305 ^{*} Benjamini-Hochberg rejects all p-values above 0.0321 to control the FDR at 0.05.

42 306
43 307 **Discussion**
44
45

46 308 The present study showed considerable non-attendance in the control group of the DLCST. Data in
47
48 309 the control group was not missing at random. Non-attenders had less favourable baseline socio-
49
50
51 310 demographic profile when compared with attendees. More importantly, individuals who did not
52
53 311 attend their annual clinical work-up had worse psychosocial status than the individuals who
54
55
56 312 attended the clinic in the previous rounds. This can be used to adjust for differential non-
57
58 313 attendance. Furthermore, these individuals also had worse psychosocial status during their missed
59
60

round (assessed in the present study in the third round). This cannot be used to adjust differential non-attendance because this information is generally not available but proves the concept.

The use of a condition-specific questionnaire is a strength of the study. Previous research has demonstrated that condition-specific questionnaires are superior to generic questionnaires when measuring psychosocial consequences in cancer screening settings.(17) Furthermore, we used an appropriate longitudinal design i.e. we collected data at the same timepoints for both *Attendees* and *Non-attendees* at various times in the study, as well as we measured psychosocial status in both groups at baseline.(18) A limitation of the study is that we did not collect psychosocial outcomes of Non-attendees in the intervention group. This study was designed to gain knowledge of factors motivating such a large drop in participation in the control group. In hindsight, data on Non-attendees in the screened group could further help us understand the reasons for differential non-response.

In addition to the DLCST, two other trials assessed psychosocial consequences in lung cancer screening with low-dose CT.(6,19) Participants in the NELSON trial were invited to complete questionnaires at baseline and at the second round of screening (two years after baseline screening). Participants in the UKLS completed a questionnaire at baseline, two weeks after randomisation/CT-scan and 10-29 months after baseline. Unlike the DLCST, in these two trials the control group were not invited to an annual visit at the screening clinic. Although there were some differences in study design, non-response rates in the control groups in these three trials were similar and in all three trials there was differential non-response between the intervention and control group. Differences between attendees and non-attendees were reported in the UKLS trial.

As in the DLCST, non-attendees had worse socio-demographic profile i.e. lower social class, and

1
2
3
4 336 they were more likely single, younger and current smokers compared with attenders. However,
5
6
7 337 these were pooled estimates for both the screening group and the control group.
8
9 338 In individuals diagnosed with cancer, anxiety and worse health-related quality of life have been
10
11 339 associated with dropout, which is consistent with our findings.(20) Since *Non-attenders* in our
12
13
14 340 study experienced a higher level of anxiety than *Attenders* in the first screening round (i.e.
15
16 341 baseline), this could have been the motivation for attending the trial; to get reassured of being
17
18
19 342 healthy.(21) Therefore, randomization to the control group may have caused disappointment, but
20
21 343 also attention drawn to not being part of a possibly beneficial intervention.(22) For example, the
22
23
24 344 secretary in the screening clinic received calls from participants randomized to the control group
25
26 345 expressing their disappointment of not being screened. Furthermore, the trial put focus on the
27
28
29 346 harms of smoking, which could have increased the anxiety and fear of disease in this subgroup
30
31 347 even more, which may have been a reason to subsequent non-attendance. Finally, missing data on
32
33
34 348 psychosocial status in a previous round may also have been a predictor for non-attendance in the
35
36 349 next screening round, which was not the scope for this study.
37
38
39 350 Low social status, younger age and current smoking status have previously been seen among
40
41 351 dropouts and non-respondents in lung health studies.(23–26) A systematic review reporting
42
43 352 dropout from longitudinal studies in elderly concluded that higher age and declining health were
44
45
46 353 high predictors of dropout. The latter is in agreement with our findings, although higher age is in
47
48 354 contrast to our findings.(27)
49
50
51 355
52
53 356 To our knowledge, this is the first cancer screening study testing hypotheses on reasons for
54
55
56 357 differential non-response empirically. The results of this study confirmed the hypotheses we made
57
58 358 in our previous study, using inverse probability weighting to adjust for differential non-
59
60

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES)

response.(3,7,28) More importantly, the results of the two other lung cancer screening trials investigating dropout are consistent with ours. Hence, it is plausible that our results are generalisable to other cancer screening trials as well.

Therefore, future cancer screening trials should concurrently assess psychosocial status during the trial, not only to be able to assess the psychosocial effect of screening, but also to use this information to adjust any effect in the trial for bias due to differential non-attendance.

Conclusions

In conclusion, *Non-attenders* in the control group in the DLCST had a worse psychosocial status and a less favourable socio-demographic profile than *Attenders*.

The results of our study contribute with evidence of non-response driven by psychosocial status, which in turn may be influenced by the screening intervention itself. This can be used to adjust cancer screening trial results for bias due to differential attendance.

Abbreviations

RCT: Randomized controlled trial; PROM: Patient-reported outcome measure; CT: Computed tomography; DLCST: Danish Lung Cancer Screening Trial; COS-LC: Consequences of screening in lung cancer; COS: Consequences of screening; CCI: Charlson comorbidity index

Declarations

Ethics approval and consent to participate

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

The Ethical Committee of Copenhagen County approved the DLCST including this observational study nested in the DLCST on 31 January 2003: approval number KA-02045.

All participants signed an informed consent form and received an information letter about the project and information about the ethical approval and data protection agency approval. The trial is registered in [Clinicaltrials.gov](https://clinicaltrials.gov) Protocol Registration System (identification no. [NCT00496977](https://clinicaltrials.gov/ct2/show/study?term=NCT00496977))

Availability of data and materials

The corresponding author can provide the questionnaires and datasets generated and analysed during the study on reasonable request.

Competing interests

None declared.

Funding

This work was supported by the Danish Ministry of Interior and Health, grant number [0900814](#).

The funding source had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author contributions

JB and HT developed and designed the study. JB, HT and the DLCST staff collected data. VS performed the statistical analyses. JM drafted the manuscript. JB, HT, BH, JFR, and VS all contributed to parts of the manuscript as well as revisions of the manuscript. All authors approved the final version of the manuscript, and no editorial assistance was received. All authors had full

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Enseignement Supérieur (ABES).

access to all data in the study and are responsible of data retention and the accuracy of the data analysis. JM and JB are guarantors of the study.

Acknowledgement

We wish to thank data manager Willy Karlsund for his contribution to generation of the databases and we also wish to thank the DLCST steering committee.

Fig.1 Flowchart, DLCST

Fig.2 Flowchart, present study

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Tierney JF. Investigating patient exclusion bias in meta-analysis. *Int J Epidemiol* [Internet]. 2004 Aug 27;34(1):79–87. Available from: <https://academic.oup.com/ije/article-lookup/doi/10.1093/ije/dyh300>

2. Zhang Y, Alyass A, Vanniyasingam T, Sadeghirad B, Flórez ID, Pichika SC, et al. A systematic survey of the methods literature on the reporting quality and optimal methods of handling participants with missing outcome data for continuous outcomes in randomized controlled trials. *J Clin Epidemiol* [Internet]. 2017 Aug;88:67–80. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/28579378>

3. Dufouil C, Brayne C, Clayton D. Analysis of longitudinal studies with death and drop-out: a case study. *Stat Med* [Internet]. 2004 Jul 30;23(14):2215–26. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/15236426>

4. Humphrey LL, Deffebach M, Pappas M, Baumann C, Artis K, Mitchell JP, et al. Screening for lung cancer with low-dose computed tomography: a systematic review to update the US Preventive services task force recommendation. *Ann Intern Med* [Internet]. 2013 Sep 17 [cited 2014 Feb 26];159(6):411–20. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/23897166>

5. Wu GX, Raz DJ, Brown L, Sun V. Psychological Burden Associated With Lung Cancer Screening: A Systematic Review. *Clin Lung Cancer* [Internet]. 2016 Sep;17(5):315–24. Available from: <http://linkinghub.elsevier.com/retrieve/pii/S1525730416300535>

6. Brain K, Lifford KJ, Carter B, Burke O, McDonald F, Devaraj A, et al. Long-term psychosocial outcomes of low-dose CT screening: results of the UK Lung Cancer Screening randomised

- controlled trial. *Thorax* [Internet]. 2016 Nov;71(11):996–1005. Available from: <http://thorax.bmj.com/lookup/doi/10.1136/thoraxjnl-2016-208283>
7. Rasmussen JF, Siersma V, Pedersen JH, Brodersen J. Psychosocial consequences in the Danish randomised controlled lung cancer screening trial (DLCST). *Lung Cancer* [Internet]. 2015;87(1):65–72. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/25433982>
 8. Pedersen JH, Ashraf H, Dirksen A, Bach K, Hansen H, Toennesen P, et al. The Danish randomized lung cancer CT screening trial--overall design and results of the prevalence round. *J Thorac Oncol* [Internet]. 2009 May [cited 2013 Sep 18];4(5):608–14. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/19357536>
 9. Brodersen J, Thorsen H, Kreiner S. Consequences of screening in lung cancer: development and dimensionality of a questionnaire. *Value Health* [Internet]. 2010 Aug [cited 2013 Oct 1];13(5):601–12. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/20345552>
 10. Aggestrup LM, Hestbech MS, Siersma V, Pedersen JH, Brodersen J. Psychosocial consequences of allocation to lung cancer screening: a randomised controlled trial. *BMJ Open* [Internet]. 2012 Jan [cited 2013 Oct 1];2(2):e000663. Available from: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3293139&tool=pmcentrez&rendertype=abstract>
 11. Heydarpour B, Saeidi M, Ezzati P, Soroush A, Komasi S. Sociodemographic Predictors in Failure to Complete Outpatient Cardiac Rehabilitation. *Ann Rehabil Med* [Internet]. 2015 Dec;39(6):863–71. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/26798599>
 12. de Graaf R, van Dorsselaer S, Tuithof M, ten Have M. Sociodemographic and psychiatric predictors of attrition in a prospective psychiatric epidemiological study among the general

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

population. Result of the Netherlands Mental Health Survey and Incidence Study-2. *Compr Psychiatry* [Internet]. 2013 Nov;54(8):1131–9. Available from: <http://linkinghub.elsevier.com/retrieve/pii/S0010440X13001284>

13. Field JK, Duffy SW, Baldwin DR, Whynes DK, Devaraj A, Brain KE, et al. UK Lung Cancer RCT Pilot Screening Trial: baseline findings from the screening arm provide evidence for the potential implementation of lung cancer screening. *Thorax* [Internet]. 2015;1–10. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/26645413>

14. McCaffery KJ. Assessing psychosocial/quality of life outcomes in screening: how do we do it better? *J Epidemiol Community Heal* [Internet]. 2004 Dec 1;58(12):968–70. Available from: <http://jech.bmj.com/cgi/doi/10.1136/jech.2004.025114>

15. Brodersen J, Thorsen H. Consequences of Screening in Breast Cancer (COS-BC): development of a questionnaire. *Scand J Prim Health Care* [Internet]. 2008 Jan [cited 2013 Oct 1];26(4):251–6. Available from: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3406644&tool=pmcentrez&rendertype=abstract>

16. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. *J R Stat Soc Ser B* [Internet]. 1995;57(1):289–300. Available from: <http://www.jstor.org/stable/2346101>

17. Brodersen J, Thorsen H, Cockburn J. The adequacy of measurement of short and long-term consequences of false-positive screening mammography. *J Med Screen*. 2004;11(1):39–44.

18. DeFrank JT, Barclay C, Sheridan S, Brewer NT, Gilliam M, Moon AM, et al. The psychological harms of screening: the evidence we have versus the evidence we need. *J Gen Intern Med*

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Enseignement Supérieur (ABES).

- [Internet]. 2015;30(2):242–8. Available from:
<http://www.ncbi.nlm.nih.gov/pubmed/25150033>
19. van den Bergh KAM, Essink-Bot ML, Borsboom GJJM, Scholten ET, van Klaveren RJ, de Koning HJ. Long-term effects of lung cancer computed tomography screening on health-related quality of life: the NELSON trial. *Eur Respir J* [Internet]. 2011 Jul [cited 2014 Oct 3];38(1):154–61. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/21148229>
 20. Mercieca-Bebber RL, Price MA, Bell ML, King MT, Webb PM, Butow PN, et al. Ovarian cancer study dropouts had worse health-related quality of life and psychosocial symptoms at baseline and over time. *Asia Pac J Clin Oncol* [Internet]. 2017 Oct;13(5):e381–8. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/27573704>
 21. Østerø J, Siersma V, Brodersen J. Breast cancer screening implementation and reassurance. *Eur J Public Health*. 2014;24(2):258–63.
 22. Wendler D, Krohmal B, Emanuel EJ, Grady C. Why patients continue to participate in clinical research. *Arch Intern Med* [Internet]. 2008 Jun 23 [cited 2013 Oct 1];168(12):1294–9. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/18574086>
 23. Snow WM, Connett JE, Sharma S, Murray RP. Predictors of attendance and dropout at the Lung Health Study 11-year follow-up. *Contemp Clin Trials* [Internet]. 2007 Jan;28(1):25–32. Available from: <http://linkinghub.elsevier.com/retrieve/pii/S1551714406001157>
 24. Nohlert E, Öhrvik J, Helgason ÁR. Non-responders in a quitline evaluation are more likely to be smokers - a drop-out and long-term follow-up study of the Swedish National Tobacco Quitline. *Tob Induc Dis* [Internet]. 2016;14:5. Available from:
<http://www.ncbi.nlm.nih.gov/pubmed/26843854>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

25. Abrahamsen R, Svendsen MV, Henneberger PK, Gundersen GF, Torén K, Kongerud J, et al. Non-response in a cross-sectional study of respiratory health in Norway. *BMJ Open* [Internet]. 2016;6(1):e009912. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/26739738>

26. Oleske DM, Kwasny MM, Lavender SA, Andersson GBJ. Participation in occupational health longitudinal studies: predictors of missed visits and dropouts. *Ann Epidemiol* [Internet]. 2007 Jan;17(1):9–18. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/17140810>

27. Chatfield MD, Brayne CE, Matthews FE. A systematic literature review of attrition between waves in longitudinal studies in the elderly shows a consistent pattern of dropout between differing studies. *J Clin Epidemiol* [Internet]. 2005 Jan [cited 2014 Mar 13];58(1):13–9. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/15649666>

28. Rotnitzky A, Robins J. Analysis of semi-parametric regression models with non-ignorable non-response. *Stat Med* [Internet]. 16(1–3):81–102. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/9004385>

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Enseignement Supérieur (ABES).

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Allocation


First round

Second round


Third round

Fourth round

Fifth round



- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31



STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	1
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	2-4
Objectives	3	State specific objectives, including any prespecified hypotheses	4
Methods			
Study design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	6
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	Not applicable
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6 and 7
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	
Bias	9	Describe any efforts to address potential sources of bias	
Study size	10	Explain how the study size was arrived at	Not applicable
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6-8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	7-8
		(b) Describe any methods used to examine subgroups and interactions	7
		(c) Explain how missing data were addressed	Not applicable
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed	Not applicable

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Continued on next page

Cross-sectional study—If applicable, describe analytical methods taking account of sampling strategy
(e) Describe any sensitivity analyses

For peer review only

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES).

Results

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Fig.1
		(b) Give reasons for non-participation at each stage	Fig.2
		(c) Consider use of a flow diagram	Fig.2
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	7
		(b) Indicate number of participants with missing data for each variable of interest	Table 1
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	N/A
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	Table 2-4
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Table 2-4
		(b) Report category boundaries when continuous variables were categorized	N/A
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	N/A
Discussion			
Key results	18	Summarise key results with reference to study objectives	9
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	10
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	10
Generalisability	21	Discuss the generalisability (external validity) of the study results	11-12
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	13

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Did psychosocial status, sociodemographics and smoking status affect non-attendance in control participants in the Danish Lung Cancer Screening Trial? A nested observational study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-030871.R3
Article Type:	Original research
Date Submitted by the Author:	25-Nov-2019
Complete List of Authors:	Malmqvist, Jessica; University of Copenhagen, Department of Public Health Siersma, Volkert; University of Copenhagen, Department of Public Health, the Research Unit for General Practice Thorsen, Hanne; University of Copenhagen, Department of Public Health, the Research Unit for General Practice Heleno, B; Universidade Nova de Lisboa, Rasmussen, Jakob; University of Copenhagen, Department of Public Health, the Research Unit for General Practice Brodersen, John; University of Copenhagen, Centre of Research & Education in General Practice Primary Health Care Research Unit, Zealand Region
Primary Subject Heading:	Public health
Secondary Subject Heading:	Research methods, General practice / Family practice
Keywords:	Bias, Mass screening, Lung neoplasms, Patient dropout

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Enseignement Supérieur (ABES).

Did psychosocial status, sociodemographics and smoking status affect non-attendance in control participants in the Danish Lung Cancer Screening Trial? A nested observational study

Jessica Malmqvist^{ac}, Volkert Siersma^a, Hanne Thorsen^a, Bruno Heleno^b Jakob Fraes Rasmussen^a, John Brodersen^{ac}

^a The Section of General Practice and Research Unit for General Practice, University of Copenhagen, Øster Farimagsgade 5, 24Q, 1014 Copenhagen, Denmark.

^b CEDOC, Chronic Diseases Research Centre, NOVA Medical School/Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, Campo dos Mártires da Pátria, 130, 1169-056 Lisbon, Portugal

^c The Primary Health Care Research Unit, Region Zealand, Denmark

Corresponding author:

Jessica Malmqvist

jessica.malmqvist@sund.ku.dk

Phone number: +45-35332583

Fax number: +45-35327946

Keywords

bias, mass screening, lung neoplasms, patient dropouts

Word count 2780

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

21

Abstract

22

Objectives: We investigated if psychosocial status, socio-demographics and smoking status

23

affected non-attendance in the control group in the randomised Danish Lung Cancer Screening

24

Trial (DLCST).

25

Design & setting: This study was an observational study nested in the DLCST. Due to large non-

26

attendance in the control group in the second screening round we made an additional effort to

27

collect questionnaire data from non-attenders in this group in the third screening round. We used

28

a condition-specific questionnaire to assess psychosocial status. We analysed the differences in

29

psychosocial status in the third and preceding rounds between non-attenders and attenders in the

30

control group in multivariable linear regression models adjusted for socio-demographics and

31

smoking status reported at baseline. Differences in socio-demographics and smoking status were

32

analysed with chi-squared tests (categorical variables) and t-tests (continuous variables).

33

Primary outcome measure: Primary outcome was psychosocial status.

34

Participants: All control persons participating in the third screening round in the DLCST were

35

included.

36

Results: Non-attenders in the third round had significantly worse psychosocial status than

37

attenders in the scales: “Behaviour” 0.77 (99% CI 0.18;1.36), “Self-blame” 0.59 (99% CI 0.14;1.04),

38

“Focus on airway symptoms” 0.22 (99% CI 0.08;0.36), “Stigmatisation” 0.51 (99% CI 0.16;0.86),

39

“Introvert” 0.56 (99% CI 0.23;0.89), and “Harms of smoking” 0.35 (99% CI 0.11;0.59). Moreover,

40

non-attenders had worse scores than attendees in the preceding screening rounds. Non-attenders

41

also reported worse socio-demographics at baseline.

42

Conclusions: Non-attenders had a significantly worse psychosocial status and worse socio-

43

demographics compared with attenders. The results of our study contribute with evidence of non-

response and attrition driven by psychosocial status, which in turn may be influenced by the screening intervention itself. This can be used to adjust cancer screening trial results for bias due to differential non-attendance.

Trial registration: The trial is registered in [Clinicaltrials.gov](https://clinicaltrials.gov) Protocol Registration System (identification no. [NCT00496977](https://clinicaltrials.gov/ct2/show/study/NCT00496977))

Article summary

Strengths and limitations

- Use of a condition-specific questionnaire with adequate psychometric properties ensured valid measures.
- Patient-reported data on non-respondents gave valuable empirical insight in drivers for non-attendance.
- Testing a previously hypothesized model for non-attendance empirically is another strength of the study.
- No comparison between non-attenders in the intervention and the control group was performed.
- No longer-term follow up on non-attenders was performed.

Introduction

Non-attendance may affect trial results and introduce bias in randomised controlled trials (RCTs).(1,2) Non-attendance reduces the power of the trial and, if non-attendance differs between the randomised groups, conventional effect estimates can be biased.(2) While we cannot change

1
2
3
4 66 the loss of power, we may remove bias due to differential non-attendance if we know and have
5
6
7 67 measured the factors that cause this non-attendance.(3) For some outcome measures, such as
8
9 68 disease incidence or mortality, non-attendance can be partially addressed if data can be obtained
10
11
12 69 from national electronic registers. However, non-attendance will be larger for outcome measures
13
14 70 that depend on direct data collection such as clinical measurements and patient reported
15
16 71 outcome measures (PROMs). Moreover, the factors driving non-attendance for these measures
17
18
19 72 may be very heterogeneous and may also be driven by the experiences of the trial participants in
20
21 73 the trial process.
22
23
24 74 The problems with differential non-attendance may be aggravated in trials assessing psychosocial
25
26 75 consequences of cancer screening as well as other interventions where it is impossible to blind
27
28
29 76 participants to allocation. Notably, a control group not offered screening may be less inclined to
30
31 77 return questionnaires enquiring into their experiences with a potentially beneficial intervention
32
33
34 78 they did not receive. However, the psychosocial dimensions of non-attendance and potential
35
36 79 consequences of these in lung cancer screening trials are only partially researched.(4–7) Since
37
38
39 80 cancer screening trials are investigating potentially life-threatening diseases there may be
40
41 81 emotional drivers of non-attendance, not typical for trials in general. Hence, it is of interest to
42
43
44 82 know which factors drive non-attendance in PROMs in cancer screening trials as this data is to be
45
46 83 collected in these trials and then used in adjusting for differential non-attendance.
47
48 84
49
50
51 85 The Danish Lung Cancer Screening Trial (DLCST) was an RCT including five annual screening rounds
52
53 86 of low-dose chest computed tomography (CT) plus clinical examinations in the intervention group
54
55
56 87 compared with annual clinical examinations only in the control group.(8) Furthermore, all the
57
58 88 participants were asked to complete a condition-specific questionnaire, measuring psychosocial
59
60

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES)

consequences of lung cancer screening at these annual clinical assessments.(9) The results showed that people experienced negative psychosocial consequences merely by participating in the trial, and that negative consequences were higher for participants allocated to the control group.(7,10) A large number of control persons did not attend the second annual examination (n=513, 26.1%) while the non-attendance rate in the intervention group was low (n=71, 3.5%) (Fig. 1). To adjust for this differential non-attendance, inverse probability weighting was used.(7) In this method the observed outcomes are weighted with the inverse of the probability of being non missing.(3) We hypothesised that these probabilities were adequately estimated from socio-demographic profile including smoking status, randomisation group and psychosocial status in previous rounds.(7,11–13)

If these hypotheses were confirmed, then these factors would explain the witnessed difference in attendance between the trial groups and could be used to render them comparable. Analysed without such adjustments the assessment of the trial groups, and thereby the means of the scores from the responses to the questionnaire from the remaining trial participants would no longer be comparable.(14) Hence, the assessment of psychosocial harms of lung cancer screening could be biased.

Therefore, the overall aim of this study was to empirically assess whether control participants who did not attend the annual clinical examination had different psychosocial profiles compared with control participants who attended the annual clinical examination.

Materials and methods

Study design and population

1
2
3
4 111 The design and study population of DLCST have been described in detail previously.(7,8) Briefly,
5
6
7 112 the DLCST was an RCT, conducted at the Copenhagen University hospital Gentofte in Denmark
8
9 113 from October 2004 to March 2010. Heavy current and former smokers (at least 20 pack-years),
10
11
12 114 aged 50-70 years old, were randomised to either five rounds of screening with low-dose CT-scans
13
14 115 including clinical examinations (n=2052) or five clinical examinations only (n=2052). In the
15
16 116 enrolment visit, participants provided socio-demographic data, lifestyle and health information
17
18
19 117 (including smoking status), completed a questionnaire on their psychosocial status and underwent
20
21
22 118 spirometry. Participants randomised to screening also had a low-dose chest CT-scan within one
23
24 119 month of randomisation. In the following screening rounds, participants in the screened and
25
26 120 control groups were invited to a visit in the screening clinic where lung function tests were
27
28
29 121 performed, and questionnaires concerning health, lifestyle, smoking habits and psychosocial
30
31 122 status were completed and lung function tests were performed. Participants randomised to
32
33
34 123 screening also received a low-dose chest CT-scan.
35
36 124 This study is an observational study nested in the DLCST. During the second screening round, the
37
38
39 125 steering committee noted that a large number of control participants did not attend the screening
40
41 126 clinic visit when compared with the number of screened participants. Thus, the committee
42
43
44 127 decided to make additional efforts to collect questionnaire data for non-attenders in the control
45
46 128 group in the third screening round to perform post hoc analyses on whether psychosocial status
47
48 129 was an influencing factor (*Fig.2*).
49
50
51 130 During the third round, participants in the control group who did not attend the annual
52
53 131 examination were contacted by phone and part 1 of the questionnaire was sent with a postage
54
55
56 132 paid envelope to those who gave their oral consent. The data was used to supplement the data
57
58
59
60

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES)

collected on site at the screening clinic.⁽⁷⁾ This yielded three groups within the control group, denoting the extent of response to the clinical examination and the questionnaire defined as:

1. *Attendees*: participants who attended the third screening round.

2. *Non-attendees*:

a) *Respondents*: participants who did not attend the annual examination but completed and returned the COS-LC after the phone interview.

b) *Non-respondents*: participants who did not attend the annual examination and did not complete the COS-LC.

Outcomes & Questionnaires

Primary outcome was psychosocial status measured with the Consequences Of Screening for Lung Cancer (COS-LC) questionnaire.⁽⁹⁾ Part 1 of COS-LC comprised nine scales measuring various aspects of consequences of screening; a second part of COS-LC addressed the screening outcome and was therefore not applicable to the present analysis. Moreover, the primary part of COS-LC included four core scales: "Anxiety", "Behaviour", "Dejection" and "Sleep" that are not lung cancer specific. These scales have originally been developed from a breast cancer screening assessment instrument.⁽¹⁵⁾ Additionally COS-LC comprised five lung cancer specific scales: "Self-blame", "Focus on airway symptoms", "Stigmatisation", "Introvert", and "Harm of smoking", which were developed from focus groups and other screening assessment instruments during the first DLCST screening round.^(9,15) Therefore, only the core scales were used in the first round, while in the following four screening rounds both the core scales and the lung cancer specific scales were used to assess psychosocial status.⁽⁹⁾

1
2
3
4 156
5
6
7 157
8
9 158
10
11
12 159
13
14 160
15
16 161
17
18
19 162
20
21 163
22
23
24 164
25
26 165
27
28
29 166
30
31 167
32
33
34 168
35
36 169
37
38
39 170
40
41 171
42
43 172
44
45
46 173
47
48 174
49
50
51 175
52
53 176
54
55
56 177
57
58
59
60

Statistics

Covariates

Socio-demographic characteristics were defined by: social class (I highest social class to V lowest social class), school and vocational education (from 9 years of elementary school to a university education), employment status, living alone, smoking status (current or former smoker), smoking history (pack-years), motivation for smoking cessation (from very strong to no wish to quit) and Charlson Comorbidity Index (CCI). Furthermore, we adjusted for region of residence (Denmark is divided into five health-administrative regions).

Statistical analyses

We performed three different analyses:

- Analyses of differences in psychosocial status in the **third** round between *Attendees* and *Non-attendees-respondents*.
- Analyses of differences in psychosocial status in the **second** round between *Attendees*, *Non-attendees-respondents* and *Non-attendees-non-respondents*.
- Analyses of differences in psychosocial status in the **first** round, between *Attendees*, *Non-attendees-respondents* and *Non-attendees-non-respondents*.

Covariates at the first screening round were compared between *Attendees* and *Non-attendees* by chi-squared tests (categorical characteristics) and t-tests (continuous characteristics). Analyses of psychosocial status at various points in the follow-up were performed in linear regression models both unadjusted and in multivariable models adjusted for sex, age, region of residence, social class, living alone, smoking status, pack years, motivation for smoking cessation and CCI. To adjust

for multiple testing we used the Benjamini-Hochberg procedure and the False Discovery Rate

(FDR) was set to 5% (16). All analyses were performed with SAS 9.4 (SAS Institute, Inc., Cary, NC).

Patient and Public Involvement

Patients and public were not involved in the design of the study.

Results

The inclusion process and participation rate of the DLCST are illustrated in Figure 1. The participation rate in the control group fell from 73.9% in the second round to 57.5% in the fourth round. The participation rate increased in the fifth, final, round (68.9%).

Figure 2 depicts the inclusion process of the present study and showed a dropout rate of 29.6% (n=607) in the third screening round with a higher distribution of *Non-attenders-non-respondents* (16.9% n=347) compared with *Non-attenders-respondents* (12.7% n=260).

In the first screening round we compared differences in socio-demographic characteristics in the two overarching groups (*Attenders, Non-attenders*) (Table 1).

Table 1, Socio-demographics

	Missing observations, total	Attendees n=1388	Non-attendees n=607	p-value*
Covariates	n	n (%)**	n(%)**	
Sex	0			0.0963
Male		773 (55.7)	313 (51.6)	
Female		615 (44.3)	294 (48.4)	
Age, mean (SD)	0	57.4 (4.7)	56.9 (4.9)	0.0538
Social class	12			0.0079
I (highest social status)		103 (7.5)	35 (5.8)	
II		296 (21.4)	100 (16.6)	
III		256 (18.5)	114 (18.9)	
IV		375 (27.2)	161 (26.7)	
V (lowest social status)		168 (12.2)	107 (17.7)	
Employed, social class uncertain		112 (8.1)	49 (8.1)	
Outside the labour market		70 (5.1)	37 (6.1)	
School education	5			0.7765
9 years of elementary school		473 (34.2)	220 (36.3)	
10 years of elementary school		541 (39.1)	231 (38.1)	
3 years of upper secondary school		363 (26.2)	153 (25.3)	
Other		7 (0.5)	2 (0.3)	
Vocational education	4			0.1267
None		124 (9.0)	72 (11.9)	
Semi-skilled worker		17 (1.2)	10 (1.7)	
Vocational training		491 (35.4)	212 (35.0)	
Short further education		142 (10.2)	48 (7.9)	
Middle range training		357 (25.8)	167 (27.6)	
Long further education		153 (11.0)	64 (10.6)	
Other		102 (7.4)	32 (5.3)	
Employment status	6			0.8394
Employed		901 (65.2)	387 (63.9)	
Studying		8 (0.6)	4 (0.7)	
Job seeking		67 (4.8)	35 (5.8)	
Retired		407 (29.4)	180 (29.7)	
CCI, mean (SD)		0.26 (0.73)	0.31 (0.83)	0.0062
Living alone	17			0.0057
No		1011 (73.5)	405 (67.3)	
Yes		365 (26.5)	197 (32.7)	

Smoking status	0			0.0122
Current smoker		1046 (75.4)	489 (80.6)	
Former smoker		342 (24.6)	118 (19.4)	
Pack-years, <i>mean (SD)</i>	4	35.7 (13.7)	35.8 (12.3)	0.4207
Motivation for smoking cessation	30			0.0540
Very strong		141 (10.3)	74 (12.4)	
Strong		324 (23.7)	166 (27.8)	
Weak		331 (24.2)	144 (24.8)	
Very weak		116 (8.5)	42 (7.0)	
No wish to quit		113 (8.3)	54 (9.0)	
Current non-smoker		342 (25.0)	118 (19.7)	

* Benjamini-Hochberg rejects all p-values above 0.0321 to control the FDR at 0.05

**Except when indicated in the leftmost column that the mean and standard deviation (SD) are listed

There was a significant difference between the study groups for social class with more *Non-attenders* in the lowest social class (V) and a greater number of *Attendees* in the highest social classes (I-II).

Moreover, *Non-attenders* had a significantly higher CCI score indicating that they had more severe or a greater number of co-occurring conditions than *Attendees*. They were also to a greater extent living alone. Furthermore, there were significantly more current smokers and a non-significant trend of a higher wish to quit smoking in the group of *Non-attenders* compared with *Attendees*.

The results of the third screening round are listed in Table 2.

Table 2, Differences in psychosocial status in the third screening round

	Range of values	Responding rate per item n/n	Attendees n=1388 mean (SD)	Non-attenders-respondents n=260 mean (SD)	p-value*	Difference in scores between the two groups mean (99%CI) ^a	p-value adjusted*
COS-scales							
Anxiety	0-18	1349/249	1.7 (2.8)	2.1 (3.2)	0.0441	0.38 (-0.13;0.89)	0.0548
Behaviour	0-21	1343/246	2.1 (3.1)	2.9 (3.8)	<0.001	0.77 (0.18;1.36)	<0.001
Dejection	0-18	1354/255	1.9 (3.0)	2.4 (3.5)	0.013	0.49 (-0.06;1.04)	0.0225
Sleep	0-12	1357/252	1.9 (2.6)	2.3 (3.0)	0.041	0.35 (-0.12;0.82)	0.0599
COS-LC scales							
Self-blame	0-15	1356/234	2.2 (2.8)	3.1 (3.8)	<0.001	0.59 (0.14;1.04)	<0.001
Focus on airway symptoms	0-24	1363/239	0.3 (0.8)	0.6 (1.0)	<0.001	0.22 (0.08;0.36)	<0.001
Stigmatisation	0-12	1361/241	1.5 (1.9)	2.1 (2.4)	<0.001	0.51 (0.16;0.86)	<0.001
Introvert	0-18	1361/243	1.3 (1.8)	1.8 (2.2)	<0.001	0.56 (0.23;0.89)	<0.001
Harms of smoking	0-6	1356/248	0.9 (1.2)	1.3 (1.6)	<0.001	0.35 (0.11;0.59)	<0.001

^a) A positive value of the difference indicates that the persons that were interviewed by phone and later returned COS-LC had on average higher scores, i.e. more negative outcomes (e.g. higher anxiety) than the persons that showed up and completed the COS-LC on site. The differences are adjusted for sex, age, region of residence, social group, living alone, smoking status, pack years, motivation for smoking cessation and CCI. The continuous values variables (age and pack years) are included as a quadratic function as to allow for possible nonlinear effects.

* Benjamini-Hochberg rejects all p-values above 0.0321 to control the FDR at 0.05.

In the core questionnaire COS (Consequences of Screening), *Non-attenders-respondents* had a statistically significant higher (worse) score than *Attendees* in the scales “Behaviour” and “Dejection”. These effects were still present when adjusting for covariates. Moreover, there was a

non-significant trend of worse scores in all COS scales among *Non-attenders-respondents*. In the lung cancer specific part of the COS-LC, *Non-attenders-respondents* had statistically significantly higher scores in all scales both crude and adjusted.

Table 3 shows differences in psychosocial status between all three subgroups in the second screening round.

Table 3, Differences in psychosocial status in the second screening round

	Range of values	Responding rate per item n/n/n	Attenders n=1388	Non- attenders- respondent s n=260	Non- attenders- non- respondents n=347	p-value*	p-value adjusted*
COS scales, mean (SD)							
Anxiety	0-18	1201/117/89	1.6 (2.7)	2.0 (3.0)	2.6 (3.8)	0.003	0.018
Behaviour	0-21	1195/114/88	1.9 (2.9)	2.4 (3.3)	2.8 (4.0)	0.012	0.071
Dejection	0-18	1217/117/87	1.8 (2.8)	2.3 (3.3)	3.0 (4.0)	<0.001	<0.001
Sleep	0-12	1220/116/88	1.7 (2.5)	2.3 (2.9)	2.6 (3.2)	<0.001	0.002
COS-LC scales, mean (SD)							
Self-blame	0-15	1210/118/88	1.7 (2.3)	2.1 (2.4)	2.6 (3.0)	<0.001	0.005
Focus on airway symptoms	0-24	1226/118/90	0.4 (0.8)	0.4 (0.8)	0.5 (0.9)	0.408	0.579
Stigmatisation	0-12	1225/121/90	1.5 (1.9)	1.8 (2.1)	2.1 (2.4)	0.028	0.146
Introvert	0-18	1223/116/90	1.3 (1.8)	1.8 (2.0)	1.4 (1.8)	0.012	0.021
Harms of smoking	0-6	1232/118/89	1.1 (1.3)	1.3 (1.3)	1.2 (1.4)	0.134	0.422

^{a)} A test for differences between the three groups adjusted for sex, age, region of residence, social group, living alone, smoking status, pack years, motivation for smoking cessation and the CCI. The continuous values variables (age and pack years) are included as a quadratic function as to allow for possible nonlinear effects.

* Benjamini-Hochberg rejects all p-values above 0.0321 to control the FDR at 0.05.

Non-attenders had significantly worse crude scores compared with *Attenders* in all the COS scales.

When adjusting for covariates the difference in scores was still significant in the three scales

1
2
3
4 287 “Anxiety”, “Dejection” and “Sleep”. In the lung cancer specific part, the crude and adjusted “Self-
5
6
7 288 blame” and “Introvert”-scale scores were significantly worse for *Non-attenders*. The difference in
8
9 289 “Stigmatisation” scale score was statistically significant in the unadjusted analyses but disappeared
10
11
12 290 in the adjusted analyses.
13
14 291 The differences in psychosocial status in the first screening round between *Attendees*, *Non-*
15
16 292 *attenders-respondents* and *Non-attenders-non-responders* showed a statistically significant worse
17
18
19 293 unadjusted score in all COS-scales, for the two *Non-attenders* subgroups (Table 4). That effect
20
21 294 disappeared in all but one scale, “Anxiety” when adjusting for covariates.
22
23
24 295
25 296

Table 4, Differences in psychosocial status in the first screening round

	Range of values	Responding rate per item n/n/n	Attendees n=1388 mean (SD)	Non-attenders- respondents n=260 mean (SD)	Non- attenders- non- respondents n=347 mean (SD)	p-value*	p-value adjusted ^a
COS-scales							
Anxiety	0-18	1353/253/334	1.46 (2.16)	1.75 (2.54)	2.11 (2.66)	<0.001	0.0028
Behaviour	0-21	1365/257/340	0.75 (1.89)	1.05 (2.44)	1.04 (2.43)	0.0134	0.0976
Dejection	0-18	1372/257/339	1.25 (2.05)	1.54 (2.48)	1.68 (2.33)	0.0018	0.0512
Sleep	0-12	1368/253/344	0.62 (1.64)	0.86 (1.98)	0.90 (1.86)	0.0072	0.0530

31
32
33
34 300
35
36 301
37
38 302
39 303
40 304
41 305
42 306
43 307
44
45
46 308
47
48 309
49
50
51 310
52
53 311
54
55
56 312
57
58 313
59
60

^a) The differences are adjusted for sex, age, region of residence, social group, living alone, smoking status, pack years, motivation for smoking cessation and CCI. The continuous values variables (age and pack years) are included as a quadratic function as to allow for possible nonlinear effects.
* Benjamini-Hochberg rejects all p-values above 0.0321 to control the FDR at 0.05.

43 307
44
45
46 308
47
48 309
49
50
51 310
52
53 311
54
55
56 312
57
58 313
59
60

Discussion

46 308 The present study showed considerable non-attendance in the control group of the DLCST. Data in
47
48 309 the control group was not missing at random. Non-attenders had less favourable baseline socio-
49
50
51 310 demographic profile when compared with attendees. More importantly, individuals who did not
52
53 311 attend their annual clinical work-up had worse psychosocial status than the individuals who
54
55
56 312 attended the clinic in the previous rounds. This can be used to adjust for differential non-
57
58 313 attendance. Furthermore, these individuals also had worse psychosocial status during their missed
59
60

round (assessed in the present study in the third round). This cannot be used to adjust differential non-attendance because this information is generally not available but proves the concept.

The use of a condition-specific questionnaire is a strength of the study. Previous research has demonstrated that condition-specific questionnaires are superior to generic questionnaires when measuring psychosocial consequences in cancer screening settings.(17) Furthermore, we used an appropriate longitudinal design i.e. we collected data at the same timepoints for both *Attendees* and *Non-attendees* at various times in the study, as well as we measured psychosocial status in both groups at baseline.(18)

A limitation of the study is that we did not collect psychosocial outcomes of Non-attendees in the intervention group. This study was designed to gain knowledge of factors motivating such a large drop in participation in the control group. In hindsight, data on Non-attendees in the screened group could further help us understand the reasons for differential non-response.

The distribution of psychosocial outcomes was left-skewed (Table 2, 3, and 4). To assure that the conclusions were not affected by this skewness, we repeated the analyses on log-transformed outcomes. The results of these sensitivity analyses reached conclusions similar to the original conclusions.

In addition to the DLCST, two other trials assessed psychosocial consequences in lung cancer screening with low-dose CT.(6,19) Participants in the NELSON trial were invited to complete questionnaires at baseline and at the second round of screening (two years after baseline screening). Participants in the UKLS completed a questionnaire at baseline, two weeks after randomisation/CT-scan and 10-29 months after baseline. Unlike the DLCST, in these two trials the control group were not invited to an annual visit at the screening clinic. Although there were some differences in study design, non-response rates in the control groups in these three trials were

1
2
3
4 337 similar and in all three trials there was differential non-response between the intervention and
5
6
7 338 control group. Differences between attenders and non-attenders were reported in the UKLS trial.
8
9 339 As in the DLCST, non-attenders had worse socio-demographic profile i.e. lower social class, and
10
11
12 340 they were more likely single, younger and current smokers compared with attenders. However,
13
14 341 these were pooled estimates for both the screening group and the control group.
15
16 342 In individuals diagnosed with cancer, anxiety and worse health-related quality of life have been
17
18
19 343 associated with dropout, which is consistent with our findings.(20) Since *Non-attenders* in our
20
21
22 344 study experienced a higher level of anxiety than *Attenders* in the first screening round (i.e.
23
24 345 baseline), this could have been the motivation for attending the trial; to get reassured of being
25
26 346 healthy.(21) Therefore, randomisation to the control group may have caused disappointment, but
27
28
29 347 also attention drawn to not being part of a possibly beneficial intervention.(22) For example, the
30
31 348 secretary in the screening clinic received calls from participants randomised to the control group
32
33
34 349 expressing their disappointment of not being screened. Furthermore, the trial put focus on the
35
36 350 harms of smoking, which could have increased the anxiety and fear of disease in this subgroup
37
38
39 351 even more, which may have been a reason to subsequent non-attendance. Finally, missing data on
40
41 352 psychosocial status in a previous round may also have been a predictor for non-attendance in the
42
43 353 next screening round, which was not the scope for this study.
44
45
46 354 Low social status, younger age and current smoking status have previously been seen among
47
48 355 dropouts and non-respondents in lung health studies.(23–26) A systematic review reporting
49
50
51 356 dropout from longitudinal studies in elderly concluded that higher age and declining health were
52
53 357 high predictors of dropout. The latter is in agreement with our findings, although higher age is in
54
55
56 358 contrast to our findings.(27)
57
58
59
60

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES)

To our knowledge, this is the first cancer screening study testing hypotheses on reasons for differential non-response empirically. The results of this study confirmed the hypotheses we made in our previous study, using inverse probability weighting to adjust for differential non-response.^(3,7,28) More importantly, the results of the two other lung cancer screening trials investigating dropout are consistent with ours. Hence, it is plausible that our results are generalisable to other cancer screening trials as well.

Therefore, future cancer screening trials should concurrently assess psychosocial status during the trial, not only to be able to assess the psychosocial effect of screening, but also to use this information to adjust any effect in the trial for bias due to differential non-attendance.

Conclusions

In conclusion, *Non-attenders* in the control group in the DLCST had a worse psychosocial status and a less favourable socio-demographic profile than *Attenders*.

The results of our study contribute with evidence of non-response driven by psychosocial status, which in turn may be influenced by the screening intervention itself. This can be used to adjust cancer screening trial results for bias due to differential attendance.

Abbreviations

RCT: Randomised controlled trial; PROM: Patient-reported outcome measure; CT: Computed tomography; DLCST: Danish Lung Cancer Screening Trial; COS-LC: Consequences of screening in lung cancer; COS: Consequences of screening; CCI: Charlson comorbidity index

Declarations

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Ethics approval and consent to participate

The Ethical Committee of Copenhagen County approved the DLCST including this observational study nested in the DLCST on 31 January 2003: approval number KA-02045.

All participants signed an informed consent form and received an information letter about the project and information about the ethical approval and data protection agency approval. The trial is registered in [Clinicaltrials.gov](https://clinicaltrials.gov) Protocol Registration System (identification no. [NCT00496977](https://clinicaltrials.gov/ct2/show/study/NCT00496977))

Availability of data and materials

The corresponding author can provide the questionnaires and datasets generated and analysed during the study on reasonable request.

Competing interests

None declared.

Funding

This work was supported by the Danish Ministry of Interior and Health, grant number [0900814](#).

The funding source had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author contributions

JB and HT developed and designed the study. JB, HT and the DLCST staff collected data. VS performed the statistical analyses. JM drafted the manuscript. JB, HT, BH, JFR, and VS all contributed to parts of the manuscript as well as revisions of the manuscript. All authors approved

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES)

the final version of the manuscript, and no editorial assistance was received. All authors had full access to all data in the study and are responsible of data retention and the accuracy of the data analysis. JM and JB are guarantors of the study.

Acknowledgement

We wish to thank data manager Willy Karlslund for his contribution to generation of the databases and statistician Christine Winther Bang for performing the log-transformed analyses. Finally, we wish to thank the DLCST steering committee.

Fig.1 Flowchart, DLCST

Fig.2 Flowchart, present study

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Tierney JF. Investigating patient exclusion bias in meta-analysis. *Int J Epidemiol* [Internet]. 2004 Aug 27;34(1):79–87. Available from: <https://academic.oup.com/ije/article-lookup/doi/10.1093/ije/dyh300>

2. Zhang Y, Alyass A, Vanniyasingam T, Sadeghirad B, Flórez ID, Pichika SC, et al. A systematic survey of the methods literature on the reporting quality and optimal methods of handling participants with missing outcome data for continuous outcomes in randomized controlled trials. *J Clin Epidemiol* [Internet]. 2017 Aug;88:67–80. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/28579378>

3. Dufouil C, Brayne C, Clayton D. Analysis of longitudinal studies with death and drop-out: a case study. *Stat Med* [Internet]. 2004 Jul 30;23(14):2215–26. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/15236426>

4. Humphrey LL, Deffebach M, Pappas M, Baumann C, Artis K, Mitchell JP, et al. Screening for lung cancer with low-dose computed tomography: a systematic review to update the US Preventive services task force recommendation. *Ann Intern Med* [Internet]. 2013 Sep 17 [cited 2014 Feb 26];159(6):411–20. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/23897166>

5. Wu GX, Raz DJ, Brown L, Sun V. Psychological Burden Associated With Lung Cancer Screening: A Systematic Review. *Clin Lung Cancer* [Internet]. 2016 Sep;17(5):315–24. Available from: <http://linkinghub.elsevier.com/retrieve/pii/S1525730416300535>

6. Brain K, Lifford KJ, Carter B, Burke O, McDonald F, Devaraj A, et al. Long-term psychosocial outcomes of low-dose CT screening: results of the UK Lung Cancer Screening randomised

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Enseignement Supérieur (ABES).

- controlled trial. *Thorax* [Internet]. 2016 Nov;71(11):996–1005. Available from: <http://thorax.bmj.com/lookup/doi/10.1136/thoraxjnl-2016-208283>
7. Rasmussen JF, Siersma V, Pedersen JH, Brodersen J. Psychosocial consequences in the Danish randomised controlled lung cancer screening trial (DLCST). *Lung Cancer* [Internet]. 2015;87(1):65–72. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/25433982>
 8. Pedersen JH, Ashraf H, Dirksen A, Bach K, Hansen H, Toennesen P, et al. The Danish randomized lung cancer CT screening trial--overall design and results of the prevalence round. *J Thorac Oncol* [Internet]. 2009 May [cited 2013 Sep 18];4(5):608–14. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/19357536>
 9. Brodersen J, Thorsen H, Kreiner S. Consequences of screening in lung cancer: development and dimensionality of a questionnaire. *Value Health* [Internet]. 2010 Aug [cited 2013 Oct 1];13(5):601–12. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/20345552>
 10. Aggestrup LM, Hestbech MS, Siersma V, Pedersen JH, Brodersen J. Psychosocial consequences of allocation to lung cancer screening: a randomised controlled trial. *BMJ Open* [Internet]. 2012 Jan [cited 2013 Oct 1];2(2):e000663. Available from: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3293139&tool=pmcentrez&rendertype=abstract>
 11. Heydarpour B, Saeidi M, Ezzati P, Soroush A, Komasi S. Sociodemographic Predictors in Failure to Complete Outpatient Cardiac Rehabilitation. *Ann Rehabil Med* [Internet]. 2015 Dec;39(6):863–71. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/26798599>
 12. de Graaf R, van Dorsselaer S, Tuithof M, ten Have M. Sociodemographic and psychiatric predictors of attrition in a prospective psychiatric epidemiological study among the general

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

population. Result of the Netherlands Mental Health Survey and Incidence Study-2. *Compr Psychiatry* [Internet]. 2013 Nov;54(8):1131–9. Available from: <http://linkinghub.elsevier.com/retrieve/pii/S0010440X13001284>

13. Field JK, Duffy SW, Baldwin DR, Whynes DK, Devaraj A, Brain KE, et al. UK Lung Cancer RCT Pilot Screening Trial: baseline findings from the screening arm provide evidence for the potential implementation of lung cancer screening. *Thorax* [Internet]. 2015;1–10. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/26645413>

14. McCaffery KJ. Assessing psychosocial/quality of life outcomes in screening: how do we do it better? *J Epidemiol Community Heal* [Internet]. 2004 Dec 1;58(12):968–70. Available from: <http://jech.bmj.com/cgi/doi/10.1136/jech.2004.025114>

15. Brodersen J, Thorsen H. Consequences of Screening in Breast Cancer (COS-BC): development of a questionnaire. *Scand J Prim Health Care* [Internet]. 2008 Jan [cited 2013 Oct 1];26(4):251–6. Available from: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3406644&tool=pmcentrez&rendertype=abstract>

16. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. *J R Stat Soc Ser B* [Internet]. 1995;57(1):289–300. Available from: <http://www.jstor.org/stable/2346101>

17. Brodersen J, Thorsen H, Cockburn J. The adequacy of measurement of short and long-term consequences of false-positive screening mammography. *J Med Screen*. 2004;11(1):39–44.

18. DeFrank JT, Barclay C, Sheridan S, Brewer NT, Gilliam M, Moon AM, et al. The psychological harms of screening: the evidence we have versus the evidence we need. *J Gen Intern Med*

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Enseignement Supérieur (ABES).

[Internet]. 2015;30(2):242–8. Available from:

<http://www.ncbi.nlm.nih.gov/pubmed/25150033>

19. van den Bergh KAM, Essink-Bot ML, Borsboom GJJM, Scholten ET, van Klaveren RJ, de Koning HJ. Long-term effects of lung cancer computed tomography screening on health-related quality of life: the NELSON trial. *Eur Respir J* [Internet]. 2011 Jul [cited 2014 Oct 3];38(1):154–61. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/21148229>
20. Mercieca-Bebber RL, Price MA, Bell ML, King MT, Webb PM, Butow PN, et al. Ovarian cancer study dropouts had worse health-related quality of life and psychosocial symptoms at baseline and over time. *Asia Pac J Clin Oncol* [Internet]. 2017 Oct;13(5):e381–8. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/27573704>
21. Østerø J, Siersma V, Brodersen J. Breast cancer screening implementation and reassurance. *Eur J Public Health*. 2014;24(2):258–63.
22. Wendler D, Krohmal B, Emanuel EJ, Grady C. Why patients continue to participate in clinical research. *Arch Intern Med* [Internet]. 2008 Jun 23 [cited 2013 Oct 1];168(12):1294–9. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/18574086>
23. Snow WM, Connett JE, Sharma S, Murray RP. Predictors of attendance and dropout at the Lung Health Study 11-year follow-up. *Contemp Clin Trials* [Internet]. 2007 Jan;28(1):25–32. Available from: <http://linkinghub.elsevier.com/retrieve/pii/S1551714406001157>
24. Nohlert E, Öhrvik J, Helgason ÁR. Non-responders in a quitline evaluation are more likely to be smokers - a drop-out and long-term follow-up study of the Swedish National Tobacco Quitline. *Tob Induc Dis* [Internet]. 2016;14:5. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/26843854>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

25. Abrahamsen R, Svendsen MV, Henneberger PK, Gundersen GF, Torén K, Kongerud J, et al. Non-response in a cross-sectional study of respiratory health in Norway. *BMJ Open* [Internet]. 2016;6(1):e009912. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/26739738>

26. Oleske DM, Kwasny MM, Lavender SA, Andersson GBJ. Participation in occupational health longitudinal studies: predictors of missed visits and dropouts. *Ann Epidemiol* [Internet]. 2007 Jan;17(1):9–18. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/17140810>

27. Chatfield MD, Brayne CE, Matthews FE. A systematic literature review of attrition between waves in longitudinal studies in the elderly shows a consistent pattern of dropout between differing studies. *J Clin Epidemiol* [Internet]. 2005 Jan [cited 2014 Mar 13];58(1):13–9. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/15649666>

28. Rotnitzky A, Robins J. Analysis of semi-parametric regression models with non-ignorable non-response. *Stat Med* [Internet]. 16(1–3):81–102. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/9004385>

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Enseignement Supérieur (ABES).

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Allocation


First round


Second round

Third round

Fourth round

Fifth round





STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	1
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	2-4
Objectives	3	State specific objectives, including any prespecified hypotheses	4
Methods			
Study design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	6
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	Not applicable
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6 and 7
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	
Bias	9	Describe any efforts to address potential sources of bias	
Study size	10	Explain how the study size was arrived at	Not applicable
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6-8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	7-8
		(b) Describe any methods used to examine subgroups and interactions	7
		(c) Explain how missing data were addressed	Not applicable
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed	Not applicable

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Continued on next page

Cross-sectional study—If applicable, describe analytical methods taking account of sampling strategy
(e) Describe any sensitivity analyses

For peer review only

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Enseignement Supérieur (ABES).

Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Fig.1
		(b) Give reasons for non-participation at each stage	Fig.2
		(c) Consider use of a flow diagram	Fig.2
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	7
		(b) Indicate number of participants with missing data for each variable of interest	Table 1
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	N/A
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	Table 2-4
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Table 2-4
		(b) Report category boundaries when continuous variables were categorized	N/A
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	N/A
Discussion			
Key results	18	Summarise key results with reference to study objectives	9
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	10
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	10
Generalisability	21	Discuss the generalisability (external validity) of the study results	11-12
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	13

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.